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VAPE AWAY: WHY A MINIMALIST REGULATORY
STRUCTURE IS THE BEST OPTION FOR FDA E-
CIGARETTE REGULATION
I. INTRODUCTION
People smoke to get a buzz.' Plain and simple. Every time a
person decides to smoke a cigarette they make a personal cost-
benefit decision. The benefits of smoking often include improved
concentration and mood as well as providing sedative and euphor-
ic effects.! On the other hand, the costs of smoking traditional,
combustible cigarettes are quite high. The adverse effects of
smoking combustible cigarettes have become common knowledge
over the past fifty years, beginning with the required warnings on
cigarette packs in the 1960s, as countless studies have affirmed
the link between cigarette smoking and a seemingly endless list
of negative health effects.' By now, study results confirming the
increased risk of several forms of cancer, birth defects, emphyse-
ma, and chronic bronchitis, just to name a few, have reached the
1. By "buzz," I am referring to the physiological and psychological effects obtained
when smoking a cigarette. Traditional, combustible cigarettes carry nicotine-laced smoke
that enters the lungs, allowing the nicotine to flow to the brain through arterial circula-
tion, which ultimately attaches to nicotinic receptors releasing various neurotransmitters.
See Neal L. Benowitz, Nicotine Addiction, 362 NEW ENG. J. MED. 2295, 2295-96 (2010).
Dopamine, one of the various neurotransmitters released, signals pleasure to the user
while also reducing stress, anxiety, and other undesirable mental states. Id.
2. P. Caponnetto et al., Electronic Cigarette: A Possible Substitute for Cigarette De-
pendence, 79 MONALDI ARCHIVES FOR CHEST DISEASE 12, 15 (2013).
3. Effects of Smoking on Your Health, BE TOBACCO FREE, http://www.betobaccofree.
hhs.gov/health-effects/smoking-healthlindex.html (last visited Apr. 14, 2014); Tobacco
Harm Reduction, RJ REYNOLDS TOBACCO, http://www.rjrt.com/pubhealth.aspx (last visited
Apr. 14, 2014) ("In 1969, the Public Health Smoking Act of 1969 required all cigarette
packaging contain the statement: Warning: The Surgeon General has determined that
cigarette smoking is dangerous to your health.").
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ears not only of "addicts" but the general public as well.4 Despite
the numerous risks of cigarette smoking, many people decide that
the benefits of smoking at least somewhat outweighs its health
costs because one in every five adults in the United States
smokes cigarettes.'
Many of those addicted to cigarettes or other tobacco products
have attempted to quit or reduce their consumption through any
means available, including nicotine gum, patches, lollipops, and,
as of recently, electronic cigarettes. In fact, United States ciga-
rette sales hit a low recently in 2005.6 A significant portion of this
decline in combustible cigarette sales may be attributed to the in-
creased sale of other tobacco products, such as nicotine gum.' In
2004, electronic cigarettes, or e-cigarettes, entered the United
States as a new alternative to combustible cigarettes and began
to provide virtually all of the benefits of smoking while nearly
eliminating all the costs.' Nicotine-infused e-cigarettes provide
the user with a familiar-looking, smokeless product without com-
bustible tobacco and the endless list of health effects associated
with it.' E-cigarettes allow users to "vape" a nicotine fluid without
4. See U.S. DEP'T OF HEALTH & HUMAN SERVS., SURGEON GENERAL'S REPORT: THE
HEALTH CONSEQUENCES OF SMOKING 860-61 (2004) [hereinafter HEALTH CONSEQUENCES
OF SMOKING], available at http://www.cde.gov/tobacco/data statistics/sgr/2004/pdfs/chap
ter7.pdf ("From 1965-1999, smoking has caused an estimated 4.1 million cancer deaths,
5.5 million CVD [cardiovascular disease] deaths, 2.1 million respiratory disease deaths,
94,000 infant deaths, and 11.9 million deaths total").
5. Questions About Smoking, Tobacco, and Health, AM. CANCER Soc'Y, http://www.
cancer.org/cancer/cancercauses/tobaccocancer/questionsaboutsmokingtobaccoandhealth/
questions-about-smoking-tobacco-and-health-how-many-use (last visited Apr. 14, 2014).
6. Melissa McNamara, U.S. Cigarette Sales Hit 55-Year Low, CBSNEWS (Mar. 9,
2006), http://www.cbsnews.com/news/us-cigarette-sales-hit-55-year-low/ (highlighting the
fact that cigarette sales, in 2005, hit their lowest point since 1951).
7. See The-wei Hu et al., Cigarette Consumption and Sales of Nicotine Replacement
Products, 9 TOBACCO CONTROL, Supp. II, 2000, at ii62-63; Gregory N. Connolly & Hillel R.
Alpert, Trends in the Use of Cigarettes and Other Tobacco Products 2000-2007, 299 J. AM.
MED. ASS'N 2629, 2629 (2008), available at http://www.jama.jamanetwork.com/article.as
px?articleid=182056&resultclick=3 (reporting that an increase in sales of traditional to-
bacco products made up for thirty percent of the decline in cigarette sales in the same pe-
riod).
8. Kerry Cork, To Vape or Not to Vape: Controversy Swirls Around E-Cigarettes, 16
NALBOH NEWSBRIEF, no. 4, 2009, at 7, available at http://www.publichealthlawcenter.org
sites/default/files/resources/article-cork-ecigarettes-12-09.pdf. While e-cigarettes first en-
tered the U.S. market in 2004, they did not become easily available in the U.S. until 2006.
See Joan Lowy, Ban Proposed on Electronic Cigarettes on Planes, NBC NEWS, http://www.
nbcnews.comlid/44518729/ns/travel-news/t/ban-proposed-electronic-cigarettes-planes/#.UO
FgZvldXiO (last visited Apr. 14, 2014).
9. Compare Cork, supra note 8 ("Others view [e-cigarettes] as far less hazardous al-
ternatives to combustible cigarettes, which include at least 60 known carcinogens . . . ."),
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inhaling the dozens of other chemical additives in combustible
cigarettes that increase carcinogenicity."o Instead of smoking,
which requires burning tobacco, vaping allows e-cigarette users to
inhale a vaporized nicotine mixture using a heated atomizer."
Vaping is not smoking. Hence, e-cigarette manufacturers often
market their products as allowing smokers to have "all the pleas-
ure and satisfaction of traditional smoking without all the health,
social, and economic problems."" However, despite the introduc-
tion of e-cigarettes and the significant decline in cigarette sales,
an incredible number of Americans still remain hooked on tobacco
and, specifically, the nicotine in it: 43.8 million Americans still
smoke cigarettes."
To say e-cigarettes have been controversial is certainly an un-
derstatement because health professionals and government regu-
lators have vigorously contested the risks associated with e-
cigarettes, as compared with combustible cigarettes. From a
quantitative perspective, the simple ingredient list in e-cigarettes
appears to be a less risky alternative to chemically-laden combus-
tible cigarettes, but health professionals and the Food and Drug
Administration ("FDA") often take a different view.14 Pending fed-
eral regulations could have a stifling impact on the sale and dis-
tribution of this useful product."
The jury is still out on whether nicotine itself poses serious
health risks to consumers, but there is virtually no dispute, even
with Questions About Smoking, Tobacco, and Health, supra note 5 ("The smoke from [ciga-
rettes and cigars] is made up of more than 7,000 chemicals, including over 60 known to
cause cancer (carcinogens).").
10. See HEALTH CONSEQUENCES OF SMOKING, supra note 4, at 860-61 tbl.7.3 (listing
diseases and other adverse health effects caused by smoking).
11. For a more detailed explanation of an e-cigarette's structure, see infra Part II.A.
12. E-CIGARETTE SOLUTION, http://www.ecigarettesolution.com/faq (last visited Apr.
14, 2014).
13. See Questions About Smoking, Tobacco, and Health, supra note 5.
14. See, e.g., Christie Aschwanden, E-Cigarettes: A Step Forward for Smokers, or a
Step into the Unknown?, THE GUARDIAN (Sept. 24, 2013), http://www.theguardian.com/soci
ety/2013/sep/24/ecigarettes-smoking-research-safety ('"There's no question that e-ciga-
rettes deliver fewer [toxic substances] than conventional cigarettes . . . .'); E-Cigaretttes:
Known and Unknown Dangers, SCl. DAILY, http://www.sciencedaily.com/releases/2014/01/
140129164653.htm (last visited Apr. 14, 2014) (noting the strong hesitancy of Loyola Uni-
versity Health System physician and smoking cessation expert Phillip McAndrew in de-
claring e-cigarettes as a truly safe smoking alternative); infra note 19 and accompanying
text.
15. Lawrence R. Deyton & Janet Woodcock, Regulation of E-Cigarettes and Other To-
bacco Products, U.S. FOOD & DRUG ADMIN. (Apr. 25, 2011), http://www.fda.gov/newseven
ts/publichealthfocus/ucm252360.htm.
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from e-cigarette skeptics, that e-cigarettes generally provide a
safer alternative to traditional cigarettes in terms of carcinogenic
chemicals." The main e-cigarette ingredient causing concern is
nicotine, but numerous studies have shown that nicotine, in small
doses, is actually not that harmful." In fact, a highly regarded
group of scientists have concluded that "nicotine itself is not espe-
cially hazardous, and that if nicotine could be provided in a form
that is acceptable and effective as a cigarette substitute, millions
of lives could be saved."" Presently, strict FDA regulation of e-
cigarettes is often proposed as a solution to stall e-cigarette sales
until enough research has determined the degree of safety of the
nicotine used in the vaping tool, but this may be the wrong direc-
tion considering the risk reduction e-cigarettes provide to com-
bustible cigarette smokers."
Strict regulation of e-cigarettes not only runs counter to the
basic purposes of the FDA, it also implicates a previous United
States Supreme Court decision, FDA v. Brown & Williamson To-
bacco Corp., which limited the FDA's regulatory power over to-
bacco products.2 0 Congress established the FDA to protect the
public health "by assuring the safety, efficacy, and security" of
drugs, devices, food, and cosmetics.2' However, drastically re-
stricting e-cigarette availability would undermine this purpose by
forcing traditional cigarette users to continue smoking their
chemically-packed combustible cigarettes. Many current e-
cigarette users previously smoked traditional, combustible ciga-
rettes, which are significantly more detrimental to human health
16. See Phillip Gardiner, E-Cigarettes: The Vapor This Time?, TOBACCO-RELATED
DISEASE RESEARCH PROGRAM 4 (Oct. 2, 2013), available at http://www.trdrp.org/docs/E-
Cigarettes%20The%20Vapor%2OThis%2oTime.pdf ("[M]any studies on e-cigarettes reveal
a host of other chemicals, metals, VOCs, and carcinogens contained in e-cigarette vapor,
most often at lower levels than in regular cigarette tobacco products.").
17. See infra Part IV.A.
18. See John Britton, ROYAL COLL. OF PHYSICIANS, Preface to HARM REDUCTION IN
NICOTINE ADDICTION: HELPING PEOPLE WHO CAN'T QUIT (2007).
19. See Linda Hurtado, Some Say Vaping E-Cigarettes Is Worse than Smoking the Re-
al Thing, ABC ACTION NEWS (Aug. 16, 2011), http://www.abcactionnews.com/news/health
/some-say-vaping-e-cigarettes-is-worse-than-smoking-the-real-thing.
20. 529 U.S. 120, 126 (2000) (holding that the FDA's attempt to regulate tobacco
products, at the time, was impermissible); see also Sottera, Inc. v. FDA, 627 F.3d 891, 895
(D.C. Cir. 2010) (striking down the FDA's attempt to regulate e-cigarettes under the Food,
Drug, and Cosmetic Act).
21. About FDA: What We Do, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/About
FDA/WhatWeDo/default.htm (last updated Sept. 19, 2013).
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than e-cigarettes.22 Therefore, to the extent strict regulations on
e-cigarettes reduce the likelihood that smokers will replace their
cigarette consumption with less dangerous e-cigarette consump-
tion, those regulations would contradict the FDA's purposes. Fur-
ther, the Supreme Court struck down a prior FDA attempt to
regulate tobacco products in 2000 as over-reaching and going be-
yond the agency's delegated authority." Even as recently as 2011,
the FDA attempted to regulate e-cigarettes through an improper
channel and a court criticized it for its constant power-grabbing
attempts. 24 In regard to e-cigarettes, the FDA should not continue
with its overreaching regulations that will inevitably waste time
in the courtroom, but instead should focus its efforts on creating a
minimalist regulatory structure that would inform the public of
the limited e-cigarette health risks while keeping the reduced-
risk vaporizers on the market.
In this comment, I will argue that the FDA should regulate e-
cigarettes, but in doing so, it should take a minimalist approach
to regulation. Instead of continuing its attempts to regulate to-
bacco products under the drug and device provisions of the Fed-
eral Food, Drug, and Cosmetic Act ("FDCA"), an incredibly strin-
gent statute, the FDA should focus its efforts under the Tobacco
Control Act ("TCA"), which is tailored specifically to regulate to-
bacco products. While the FDA has extensive regulatory options
under the TCA, much of this authority should not be applied to e-
cigarettes. Part II will provide background information on e-
cigarettes generally as well as steps the FDA has taken to regu-
late e-cigarettes and other tobacco products. E-cigarettes have
been in the U.S. market for nearly eight years, but the FDA has
yet to provide e-cigarette manufacturers with significant guide-
lines to facilitate compliance with its regulations. Instead, the
FDA has only attempted to block e-cigarette imports using FDCA
"authority" that the Supreme Court had to remind the FDA that
it lacked in Brown & Williamson. Part III addresses the FDA's
limited regulatory ability under the TCA and describes why it has
22. Are E-Cigarettes Better for Your Health? The Doctors Weigh in. .. , ADP HEALTH-
INSIGHTS, http://www.adphealthinsights.com/landing/ecigs.php (last visited Apr. 14, 2014)
("In the United States alone, over 700,000 smokers have already switched to electronic
cigarettes.").
23. Brown & Williamson, 529 U.S. at 126.
24. Sottera, 627 F.3d at 895; see also Smoking Everywhere, Inc. v. FDA, 680 F. Supp.
2d 62, 78 (D.D.C. 2010) ("This case appears to be yet another example of FDA's aggressive
efforts to regulate recreational tobacco products as drugs or devices under the FDCA.").
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no regulatory authority over e-cigarettes under the FDCA. Unlike
the TCA, if the courts interpret the FDCA to apply to e-cigarettes,
the FDCA would become a convoluted statute that produces an
absurd result: an inevitable ban on many tobacco products. On
the other hand, Congress enacted the TCA precisely to give the
FDA authority over tobacco products that it did not previously
have under the FDCA. While the TCA does not confer as much
power on the FDA, when compared to the FDCA, the TCA is spe-
cifically tailored to address health and safety issues directly re-
lated to tobacco products. Simply, the TCA is the Tobacco Control
Act and the FDA should exercise its authority to regulate e-
cigarettes under that statute rather than under the FDCA, a
statute that grants it no such authority. Part IV presents alterna-
tives to aggressive regulation of e-cigarettes as well as the bene-
fits of a minimalist federal regulatory scheme that allows e-
cigarette and other tobacco product users to fully benefit from the
potentially reduced health risks of e-cigarettes. I will argue that
the FDA should only set strict regulations for advertising, sale to
minors, and product labeling/standards under the TCA while ab-
staining from requiring pre-market clinical tests that would take
e-cigarettes out of consumers' hands. Using the federal regula-
tions as a base, in accordance with the TCA, states would be able
to strengthen regulation, but only in terms of e-cigarette conduct,
such as amending public smoking bans to include e-cigarette vap-
ing. Though it may seem like e-cigarettes are a regulatory "Wild
West," limited FDA regulation of e-cigarettes under the TCA
would actually improve public health by allowing the overwhelm-
ing number of combustible cigarette smokers a vaping alternative
that is likely not as harmful as smoking traditional cigarettes .
II. E-CIGARETTES AND THE FEDERAL REGULATORY BACKGROUND
E-cigarettes are a novel product, introduced in the United
States less than a decade ago,26 but the tobacco industry has
played an integral role throughout U.S. history. Tobacco has been
used in the United States since 1612, but it was not until the
1960s that scientists realized the adverse health effects linked to
25. Melissa Block, E-Cigarettes: A Nearly $2bn Industry, A Regulatory Wild West,
NPR (Oct. 21, 2013, 4:37 PM), http://www.npr.org/2013/10/21/239269426/e-cigarettes-a-
nearly-2bn-industry-a-regulatory-wild-west.
26. Cork, supra note 8, at 7; Lowy, supra note 8.
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tobacco combustion. 27 As a result of the negative health implica-
tions associated with combustible cigarettes, numerous alterna-
tives have been introduced in attempts to curb cigarette addic-
tion. Some of these products have failed whereas others, such as
nicotine gum, have endured for quite a while.28 E-cigarettes,
though, offer an advantage that past and present products do not:
e-cigarettes give users the tactile feel and familiarity of a combus-
tible cigarette while also delivering nicotine not laden with hun-
dreds of chemicals. E-cigarettes have the potential to have an in-
credible, positive impact on the smoking community with the
potential to reduce the tobacco-related death toll from 400,000 to
400 a year.2 9
A. What Is an E-Cigarette?
Tobacco usage in the United States pre-dates the Revolution-
ary War and tobacco's rootedness in American culture has made
it nearly impossible to eradicate despite the scientific studies
linking tobacco usage to numerous forms of cancer and other dis-
eases-making the introduction of the e-cigarette, a product with
the potential to all but eliminate combustible cigarettes in the
United States, all the more appealing. In the United States, Na-
tive Americans used tobacco products for medicinal and ceremo-
nial purposes, but in 1612 the first commercial crop was cultivat-
ed in Virginia.o From 1612 forward, tobacco cigarettes grew in
popularity, especially in the years following the Civil War." Not
until 1964, though, were the adverse health effects associated
with smoking combustible cigarettes widely known in the United
States.32 That year, a 387-page report released by the newly
formed Surgeon General's Advisory Committee on Smoking and
27. Matthew R. Herington, Tobacco Regulation in the United States: New Opportuni-
ties and Challenges, 23 HEALTH LAW., no. 1, at 13 (2010); A Brief History of Tobacco, CNN,
http://www.edition.cnn.comfUS/9705/tobaccolhistory/ (last visited Apr. 14, 2014).
28. See Jake E. Henningfield & John Slade, Tobacco Dependence Medications: Public
Health and Regulatory Issues, 53 FOOD & DRUG L.J. (SUPPLEMENT) 75, 86-87 (1998).
29. E Cigarettes May Cover 2 of the Top 10 New Year's Resolution According to Some
Experts and Reports, BUS. JOURNALS (Jan. 4, 2010), http://www.bizjournals.com/prnews
wirelpress releases/2010/01/04/SF31533 [hereinafter New Year's Resolution] (statement of
Joel Nitzkin, Chair of the Tobacco Control Task Force for the American Association of
Public Health Physicians).
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Health highlighted startling facts associated with smoking, in-
cluding "that the average smoker is nine to [ten] times more like-
ly to get lung cancer than" a non-smoker, while also listing specif-
ic carcinogens in cigarette smoke." Since then, the issues with
combustible cigarettes have been documented time and time
again as the small, paper wrapped nicotine delivery systems con-
tain hundreds of toxic chemicals, of which sixty-nine have been
found to cause cancer, not including the carcinogenic smoke re-
leased.3 4 With the Surgeon General's report raising awareness
about the adverse health effects of cigarettes, researchers in the
late 1960s began to study ways to get nicotine to cigarette users
without the harmful effects associated with combustible ciga-
rettes." In short, they developed nicotine replacement therapies
to deliver nicotine in a healthier way. As a result, nicotine re-
placement therapies taking the form of gum, inhalers, skin
patches, and nasal sprays flooded the markets. In 2004, a novel
product marketed as a recreational alternative to combustible
cigarettes was introduced to the United States: electronic ciga-
rettes.
Electronic cigarettes, commonly referred to as e-cigarettes, are
smokeless, flameless, battery-powered devices that vaporize liq-
uid nicotine for the user to inhale." The devices were first patent-
ed in China in 2003 and reached American markets the following
year." While the nicotine in e-cigarettes is derived from tobacco,
the e-cigarette itself contains either very small amounts of tobac-
co or none at all." E-cigarettes, therefore, allow the user to satisfy
a nicotine craving, and get a "buzz," without ingesting most of the
33. Id.; see History of the Surgeon General's Reports on Smoking and Health, CTRS.
FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/tobaccoldata statistics/sgr/his
tory/index.htm (last updated July 6, 2009).
34. Harms of Smoking and Health Benefits of Quitting, NAT'L CANCER INST., http://
www.cancer.gov/cancertopics/factsheet/Tobacco/cessation (last visited Apr. 14, 2014).
35. Nicotine Replacement Therapy, NICORETTE, http://www.nicorette.in/nicorette/nico
tine-replacement (last visited Apr. 14, 2014).
36. Nicotine Replacement Therapy, MEDLINEPLUS, http://www.nlm.nih.gov/medline
plus/ency/article/007438.htm (last visited Apr. 14, 2014).
37. Barbara Demick, A High-Tech Approach to Getting a Nicotine Fix, L.A. TIMES
(Apr. 25, 2009), http://articles.latimes.com/2009/apr/25/world/fg-china-cigarettes25.
38. Cork, supra note 8, at 7. Once again, while introduced in 2004, they became wide-
ly available in the U.S. markets a few years later. See, e.g., Lowy, supra note 8.
39. Recent Case, D.C. Circuit Rules FDA Cannot Block E-Cigarette Imports-Sottera,
Inc. v. FDA, 37 AM. J.L. & MED. 194, 194 (2011) (citing Sottera, Inc. v. FDA, 627 F.3d 891,
893 (D.C. Cir. 2010)) ("While the nicotine in e-cigarettes is derived from tobacco, the e-
cigarette itself contains no tobacco.").
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harmful chemicals contained in traditional tobacco products such
as cigarettes, cigars, and smokeless tobacco. 40 Although some or-
ganizations claim that the precise benefits and risks of e-
cigarettes are still "uncertain," other groups, such as the Ameri-
can Association of Public Health Physicians, actually recommend
that those suffering from a nicotine addiction should consider us-
ing e-cigarettes as a long-term replacement for smoking combus-
tible cigarettes.4 1 Organizations on both sides of the debate,
though, agree that e-cigarettes should not be recommended for
new users as a primarily recreational product.42
Naturally, the perceived benefits of e-cigarette vaping, as op-
posed to smoking combustible cigarettes, have led to a surge in
the e-cigarette industry, which now has about 3.5 million users in
the United States.43 From a market perspective, e-cigarette sales
are predicted to exceed one billion dollars in U.S. sales by Decem-
ber 2014.44 The vaporizers are sold both on the Internet and in
stores and can cost anywhere from thirty to one hundred dollars
for a starter kit and around ten dollars for a nicotine cartridge
five-pack refill." The estimated yearly cost of replacement car-
40. See Caponnetto et al., supra note 2, at 13-14.
41. Principles to Guide AAPHP Tobacco Policy, AM. ASS'N OF PUB. HEALTH
PHYSICIANS, http://www.aaphp.org/Tobacco (last visited Apr. 14, 2014); Questions and An-
swers on Electronic Cigarettes or Electronic Nicotine Delivery Systems (ENDS), WORLD
HEALTH ORG. (July 9, 2013), http://www.who.int/tobacco/communications/statements/elect
ronicscigarettes/en/.
42. See RACHEL GRANA ET AL., BACKGROUND PAPER ON E-CIGARETTES (ELECTRONIC
NICOTINE DELIVERY SYSTEMS), WHO COLLABORATING CTR. ON TOBACCO CONTROL 25
(2013); Who Opposes E-Cigarettes, and Why?, THE ECONOMIST (June 17, 2013, 11:50 PM),
http://www.economist.com/blogs/economist-explains/2013/06/economist-explains-11.
43. Mary Diduch, North Jersey Companies See Growth Along with E-Cigarette Indus-
try, NORTHJERSEY.COM (Jan 18, 2013), http://www.northjersey.com/news/187414911
NorthJersey-companies see.growth-along-with-e-cigarette industry.html. Just four
years prior to Diduch's article, a study found only 300,000 e-cigarette users in the United
States in 2009 as opposed to 3.5 million in 2013. See Ron Scherer, Electronic Cigarettes: In
Need of FDA Regulation?, CHRISTIAN SCI. MONITOR (Oct. 17, 2009), http://www.csmoni
tor.com/USA/Society/2009/1017/p02s03-ussc.html.
44. See Diduch, supra note 43; see also Mariana Lopes, E-Cigarettes: A Burning Ques-
tion for U.S. Regulators, REUTERS (Dec. 11, 2013), http://www.reuters.com/article/2013/
12/11/us-usa-ecigarettes-idUSBRE9BAOZT2013211 (explaining that the market for e-
cigarettes is expected to surge to up to $10 billion by 2017); John Tierney, A Tool to Quit
Smoking Has Some Unlikely Critics, N.Y. TIMES (Nov. 7, 2011), http://www.nytimes.com/
2011/11/08/science/e-cigarettes-help-smokers-quit-but-they-have-some-unlikely-critics.ht
ml? r=0.
45. Ben McCampbell, E-Cigarettes: Unanswered Questions, AN APPLE A DAY (Feb. 28,
2014), http://www.anapplemag.com/article/wellness/e-cigarettes-unanswered-questions;
Liz Neporent, 5 Things You Need to Know About E-Cigarettes, ABC NEWS (Sept. 24, 2013),
http://abcnews.go.com/Healthlfacts-cigarettes/story?id=20345463#2; see, e.g., MIG CIGS,
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tridges is about six hundred dollars, which, when compared to the
one thousand dollars plus a year that a "pack-a-day" combustible
cigarette smoker pays, is fairly economical. 46
Structurally, e-cigarettes are made of three basic parts: (1) a
nicotine cartridge, (2) an atomizer that vaporizes the nicotine
through heat, and (3) a battery." E-cigarettes come in a variety of
designs in addition to the traditional cigarette shape, such as a
pen or USB drive, and the nicotine mixtures, often referred to as
"juice," can be purchased in a variety of flavors.48 Instead of using
a match or lighter, the user simply inhales. The device then de-
tects the airflow and activates the atomizer, and the nicotine-
water-propolyne glycol mixture is vaporized. Physically, most e-
cigarettes both look and feel similar to a traditional, combustible
cigarette, but do not contain the array of chemical, carcinogenic
ingredients found in combustible cigarettes.5 0 As a result, e-
cigarettes may be viewed as a safer alternative to combustible
cigarettes.
While the debate regarding e-cigarette safety will inevitably
linger, the vaporizers appear to be significantly safer than com-
bustible cigarettes." Many view e-cigarettes as a lesser evil com-
http://www.migcigs.com/com/5-pack-flavor-cartridges-p/crt5.htm (last visited Apr. 14,
2014); VAPORZONE, http://www.vaporzone/comle-liquid-cartridges/vaporzone-express-vani
Ila-cartridges.html (last visited Apr. 14, 2014); V2 CIGS, http://www.v2cigs.com/products/
v2-flavor-cartridges-5-pack#.Uz68RtyM5gO (last visited Apr. 14, 2014).
46. Neporent, supra note 45.
47. See Nathan K. Cobb et al., Novel Nicotine Delivery Systems and Public Health:
The Rise of the "E-Cigarette," 100 AM. J. PUB. HEALTH 2340, 2341 (2010), available at
http://www.ncbi.nlm.nih.gov/pmedarticles/PMC2978165/pdfl2340.pdf (stating that the refill
cartridges that contain the nicotine liquid used in e-cigarettes are sometimes referred to
as "juice"); Wendy Koch, E-Cigarettes: No Smoke, but Fiery Debate over Safety, USA TODAY
(Sept. 17, 2012), http://usatoday30.usatoday.com/news/health/story/2012-08-18/elec tronic-
cigarettes-smokeless-vaping-risks/57121894/1.
48. Susan Cassidy, How Electronics Cigarettes Work, HowSTUFFWORKs, http://www.
science.com/innovationleveryday-innovationstelectronic-cigarette.htm/printable (last visit-
ed Apr. 14, 2014); Electronic Cigarettes (e-cigarettes), U.S. FOOD & DRUG ADMIN., http://
science.howstuffworks.com/innovationleveryday-innovations/electronic-cigarette.htm/prin
table (last visited Apr. 14, 2014) [hereinafter Electronic Cigarettes].
49. Sottera, Inc. v. FDA, 627 F.3d 891, 893 (D.C. Cir. 2010).
50. See Caponnetto et al., supra note 2, at 13, 16; cf. U.S. DEP'T HEALTH & HUMAN
SERVS., SURGEON GENERAL'S REPORT: How TOBACCO SMOKE CAUSES DISEASE-THE
BIOLOGY AND BEHAVIORAL BASIS FOR SMOKING-A'ITRIBUTABLE DISEASE, available at
http://www.ncbi.nlm.nih.gov/books/NBK53017/ (last visited Apr. 14, 2014) (discussing a
number of non-cigarette products designed to mimic the appearance of traditional ciga-
rettes).
51. See infra Part IVA.
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pared to tobacco cigarettes,52 while others are cautious about the
safety of e-cigarettes in the absence of extensive FDA testing.53 It
is at precisely this point where the contentious debate over the
marketing and use of e-cigarettes often occurs. While there are
certainly some health and safety concerns regarding e-cigarettes,
there is a strong possibility that e-cigarettes will improve public
health: if effective at replacing traditional tobacco products, e-
cigarettes could significantly decrease the number of tobacco us-
ers, and therefore the prevalence of tobacco-related health prob-
lems.54 Despite the disagreements, e-cigarette supporters and crit-
ics would agree that there is not an abundance of independent,
reliable data evaluating the benefits and risks of e-cigarettes both
as a recreational product as well as a nicotine replacement op-
tion." Although there is no substantial evidence that e-cigarettes
are indeed dangerous to consumers, the FDA has attempted to
impose strict regulations on e-cigarettes just as they attempted to
do, albeit unsuccessfully, with combustible cigarettes. At this
point, strict regulation would be both premature and detrimental
to prior combustible cigarette smokers who have begun to use e-
cigarettes as an alternative.
B. FDA's Recent Regulation Attempts
The federal government has long excluded cigarettes and other
similar tobacco products from regulation. In 1914, the FDA's pre-
decessor agency, the Bureau of Chemistry, claimed that it only
had authority to regulate a tobacco product if the tobacco prod-
uct's labeling indicated use for "the cure, mitigation, or preven-
tion of diseases."" On the contrary, if the product's labeling indi-
52. See Danielle Dellorto, FDA Hazy on E-Cigarettes' Safety, CNN (Mar. 13, 2009),
http://www.cnn.com/2009/HEALTH/03/13/ecigarettes.smoking/.
53. See Kian Ivey, As E-cigarette Use Increases, Experts Investigate Health Risks,
BROWN DAILY HERALD (Dec. 6, 2013), http://www.browndailyherald.com/2013/12/06/e-ciga
rette-use-increases-experts-investigate-health-risks/; Popularity Surges for E-Cigarettes,
but Health Questions Unanswered, ORAL CANCER NEWS (Feb. 22, 2011), http://www.oral
cancernews.org/wp/popularity-surges-for-e-cigarettes-but-health-questions-unanswered/.
54. In the United States each year, smoking accounts for more 480,000 deaths. See
CTRS. FOR DISEASE CONTROL & PREVENTION, Adult Cigarette Smoking in the United
States: Current Estimates, http://www.cd.gov/tobacco/data-statistics/fact-sheets/adult-da
ta/cigsmoking/ (last visited Apr. 14, 2014).
55. See Thomas J. Glynn, Electronic Cigarettes-Boon, Bane, Blessing, or Boondoggle?,
AM. CANCER SOC'Y (May 3, 2011), http://www.cancer.org/cancer/news/expertvoices/post/
2011/05/03/electronic-cigarettes-e28093-boon-bane-blessing-or-boondoggle.aspx.
56. USDA BUREAU OF CHEMISTRY, SERVICE AND REGULATORY ANNOUNCEMENTS 21,
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cated use for "smoking or chewing or as snuff," which were not
considered medicinal uses, then the agency did not have regulato-
ry authority." Fast forward to 1964-when the FDA took a simi-
lar stance, the Surgeon General stated that the FDA did not have
"authority in existing laws governing [the FDA]" to regulate com-
bustible cigarettes." Even in 1980, when public health groups
pressured the FDA to regulate nicotine cigarettes as drugs under
the FDCA, the FDA continued to claim that cigarettes marketed
without health claims were not within the FDA's regulatory pur-
view.59
In 1996, the FDA changed their usual practice of abstaining
from tobacco product regulation. David Kessler, the FDA Com-
missioner at the time, issued a final rule asserting FDA regulato-
ry authority over tobacco products under the FDCA.60 The FDCA
is a massive statute granting the FDA extensive jurisdiction over
a wide swath of products, including food, drugs, cosmetics, and
medical devices that, if applied to e-cigarettes, would expose them
to "the more onerous regulatory burdens for drugs and devices
merely because they claim to be healthier alternatives to tradi-
tional tobacco products."6 ' Under Kessler's final rule, the FDA
concluded that the FDCA authorized the FDA to regulate nicotine
as a drug and cigarettes as a combination drug and medical de-
vice product.6 ' Following this abruptly announced authority, the
24 (Apr. 2, 1914), available at http://legacy.library.ucsf.edutid/qvx6COO/pdf; see Smoking
& Tobacco Use: Legislation, CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.
cdc.gov/tobaccoldata-statistics/by-topic/policylegislation/ (last visited Apr. 14, 2014).
57. See SERVICE AND REGULATORY ANNOUNCEMENTS, supra note 56.
58. See FDA v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 145 (2000).
59. See, e.g., Letter from the Food & Drug Admin. to John F. Banzhaf, III & Peter N.
Georgiades, Action on Smoking and Health (Nov. 25, 1980), available at http://www.to
baccodocuments.org/pm/2060433121-3132.html.
60. Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless
Tobacco to Protect Children and Adolescents, 61 Fed. Reg. 44,396, 44,396 (Aug. 28, 1996)
(to be codified at 21 C.F.R. pts. 801, 803, 804, 807, 820, 897); cf. Marian Burros, F.D.A.
Commissioner Is Resigning After 6 Stormy Years in Office, N.Y. TIMES (Nov. 26, 1996),
http://www.nytimes.com/1996/11/26/us/fda-commissioner-is-resigning-after-6-stormy-
years-in-office.html (stating Kessler resigned in November 1996, following the release of
the Federal Register).
61. Smoking Everywhere, Inc. v. FDA, 680 F. Supp. 2d 62, 75 (D.C. Cir. 2010); see
Food, Drug, and Cosmetic Act (FDCA), Pub. L. No. 75-717, 52 Stat. 1040 (1938).
62. Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless
Tobacco to Protect Children and Adolescents, 61 Fed. Reg. at 44,397.
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FDA promulgated a final rule to reduce tobacco consumption
through labeling, promotion, and access restrictions."
Controversial does not begin to describe this rule, which gener-
ated over 700,000 comments during the regulation's required no-
tice and comment period.64 After the promulgation of the final
rule, tobacco manufacturers, retailers, and advertisers quickly
filed suit to challenge the rule, arguing that the FDA's regulation
went far beyond its authority under the FDCA." In 1998, the
Fourth Circuit agreed with one of these challenges in Brown &
Williamson Tobacco Corp. v. FDA: it held that the FDA did not
have authority to regulate tobacco products under the FDCA."
The Supreme Court heard Brown & Williamson on appeal that
same year and agreed with the Fourth Circuit, stating that Con-
gress had "clearly precluded the FDA from asserting jurisdiction
to regulate tobacco products."" Neither of the courts afforded
Chevron deference to the FDA because the FDCA as a whole, and
when read in light of subsequent tobacco-specific legislation,
"gives the agency no authority to regulate tobacco products as
customarily marketed."6 8 Chevron deference, which generally
means a court will defer to an agency's interpretation of a statute
when that interpretation is reasonable, usually results in a high
win rate for the respective agency." Only when an agency is act-
ing clearly beyond the scope of authority it was given by Congress
to implement a statute will a court refuse to extend Chevron def-
erence." The Supreme Court did not refute that the nicotine in
tobacco was intended to affect the structure or function of the
63. See id. at 44,397-98.
64. FDA v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 126-27 (2000); see Reg-
ulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Pro-
tect Children and Adolescents, 61 Fed. Reg. at 44,418.
65. See Lars Noah & Barbara A. Noah, Nicotine Withdrawal: Assessing the FDA's Ef-
fort to Regulate Tobacco Products, 48 ALA. L. REV. 1, 5-6 (1996); see also Barnaby J. Feder,
Tobacco Curbs Face Legal Fight, N.Y. TIMES (Aug. 24, 1996), http://www.nytimes.com/
1996/08/24/us/tobacco-curbs-face-legal-fight.html.
66. 153 F.3d 155, 176 (4th Cir. 1998); see infra Part III.B.2.
67. Brown & Williamson, 529 U.S. at 126.
68. Id. at 159. If tobacco products are not "customarily marketed" for ordinary recrea-
tional use and instead are marketed as therapeutic products, the FDA does have jurisdic-
tional authority under the FDCA to regulate the product as a drug/device. See infra Part
III.B.
69. See WILLIAM N. ESKRIDGE ET. AL., CASES AND MATERIALS ON STATUTORY
INTERPRETATION 824 (2012) (noting that when the Court applies the Chevron framework,
the agency wins 76.2% of time, representing a very high agreement rate).
70. See id. at 645.
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human body, but instead reasoned that allowing the FDA to regu-
late tobacco products, namely cigarettes, under the FDCA would
require the FDA to ban them altogether.' A ban, the Court con-
tinued, would be contrary to Congress' intent, which favored in-
forming consumers about adverse health risks of tobacco use in-
stead of harming the nation's economy through an outright ban.72
In turn, Brown & Williamson makes clear that regulating tobacco
products under the FDCA simply does not make sense.
After Brown & Williamson, and the FDA's subsequent removal
of the regulations, Congress recognized the regulatory gap in the
FDCA and enacted the Family Smoking Prevention and Tobacco
Control Act of 2009 ("TCA") to provide the FDA with comprehen-
sive regulatory authority over tobacco products." Congress enact-
ed the TCA in part "to provide new and flexible enforcement au-
thority to ensure that there is effective oversight of the tobacco
industry efforts to develop, introduce, and promote less harmful
tobacco products."" This created a two-tiered system where the
FDA could regulate food, drugs, and cosmetics through the FDCA
and tobacco products through the TCA. Despite the TCA's clear
grant of authority to the FDA to regulate tobacco products, and
the Court's earlier decision in Brown & Williamson, the FDA at-
tempted to reassert its purported authority to regulate tobacco
products under the FDCA in 2009.7' This time the FDA targeted
e-cigarettes by denying import shipments of e-cigarettes entry in-
to the United States.
E-cigarettes fall within the TCA's broad definition of "tobacco
product," and therefore cannot be considered a drug or device un-
der the FDCA. Simply, e-cigarettes contain nicotine, which is de-
71. Brown & Williamson, 529 U.S. at 135; see id. at 162 (Breyer, J., dissenting) (con-
firming the majority did not deny that cigarettes are "'intended to affect' the body's 'struc-
ture' and 'function"'); see also 21 U.S.C. § 360c(a)(1)(C) (2012) (defining Class III device).
72. Brown & Williamson, 529 U.S. at 139 ("[The collective premise of these statutes
is that cigarettes and smokeless tobacco will continue to be sold in the United States. A
ban of tobacco products by the FDA would therefore plainly contradict congressional poli-
cy.").
73. 21 U.S.C. § 387 note (2012) (Findings subsec. 7) ("Federal and State governments
have lacked the legal and regulatory authority and resources they need to address com-
prehensively the public health and societal problems caused by the use of tobacco prod-
ucts.").
74. Id. (Purpose subsec. 4) (emphasis added).




rived from tobacco, and the TCA gives the FDA authority to regu-
late "any product made or derived from tobacco."" Therefore, the
FDA has claimed that they plan to focus their efforts on creating
a comprehensive regulatory scheme to regulate e-cigarettes under
the TCA." That regulatory scheme has been in the making for
over two years, but the FDA is expected to finally propose it in
the near future and will most likely include stringent e-cigarette
regulation with the potential to remove e-cigarettes from the
market to undergo pre-market clinical tests." Some e-cigarette
manufacturers have also agreed that their product should be reg-
ulated, but, consistent with the FDA's claim, under the TCA ra-
ther than the more stringent FDCA. 0 Despite the FDA's letter of
intent, there is certainly still the possibility that the FDA will at-
tempt to regulate e-cigarettes under the FDCA because relevant
case law is quite limited. Further, several critics and scholars be-
lieve the FDCA is still a viable option for e-cigarette regulation."
Currently, though, e-cigarettes are distributed largely without
government regulation and oversight for quality control, although
other tobacco products, such as combustible cigarettes, are regu-
lated." Accordingly, the FDA should regulate e-cigarettes under
the TCA.
77. 21 U.S.C. § 321(rr)(1) (2012).
78. See Deyton & Woodcock, supra note 15.
79. See Megan McArdle, E-Cigarettes: A $1.5 Billion Industry Braces for FDA Regula-
tion, BLOOMBERG BUSINESSWEEK (Feb. 6, 2014), http://www.businessweek.com/articles/
2014-02-06/e-cigarettes-fda-regulation-looms-for-l-dot-billion-industry#pl; Sara Zborovski,
The Regulation of E-Cigarettes: Trying to Fit a Square Peg into a Round Hole?,
HUFFINGTON POST BLOG (Dec. 19, 2013, 2:24 PM), http://www.huffingtonpost.com/sara-
zborovskile-cigarette-regulation_b_4468667.html; see also Deyton & Woodcock, supra note
15 (noting the FDA's intent to propose a regulation that would extend the Agency's "tobac-
co product" authorities in Chapter IX of the FDCA).
80. See Daniel Fisher, Will Taxes and Regulation Rein in the Booming E-Cigarette
Market?, FORBES (Oct. 2, 2013), http://www.forbes.com/sites/danielfisher/20131 10/02/will-
taxes-and-regulation-rein-in-the-booming-e-cigarette-market; see infra Part III.A.1.
81. See The FDA & Deeming Regulations of E-Cigarettes, CASAA, http://www.casaa.
org/deemingjregulations.html (last visited Apr. 14, 2014).
82. Anna Edney, FDA Scrutinizes E-Cigarette Marketing, IDAHO STATESMAN (Oct. 21,
2013), http://www.idahostatesman.com/2013/10/21/2826018/fda-scrutinizes-e-cigarette-ma
rketing.html. While combustible cigarettes are regulated under the TCA, nicotine gum is
regulated under the FDCA because it claims a therapeutic benefit. See Electronic Ciga-
rettes, supra note 48; Michael Siegel, FDA Reply Brief in NJOY Electronic Cigarette Case
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III. LIMITED REGULATORY ABILITY OF THE FDA UNDER THE TCA
This Part argues that, despite the limited case law directing
the FDA to regulate e-cigarettes under the TCA and critics that
believe that FDCA regulation is more appropriate, the FDA must
regulate e-cigarettes under the TCA. Given the FDA's prior at-
tempts to reach beyond its historically recognized authority by
promulgating regulations over tobacco products under the FDCA,
the FDA might attempt to promulgate future e-cigarette regula-
tions under the FDCA." This Part will analyze both why the TCA
is the appropriate regulatory avenue and why the FDCA is an in-
appropriate regulatory avenue.
A. The FDA May Only Regulate E-Cigarettes Under the TCA
1. Purpose of the TCA and the Potential Effect on E-Cigarettes
The argument that e-cigarettes, which are tobacco products,
should be subject to FDCA regulation expressly contradicts provi-
sions in the TCA. The TCA clarifies that tobacco products "shall
not be subject to the provisions of subchapter V [Drugs and De-
vices]" of the FDCA." Further discussion is hardly necessary as
the TCA makes clear that if something falls under the TCA's def-
inition of a tobacco product-a product made or derived from to-
bacco-then it shall not be regulated under the Drugs and Devic-
es provisions of the FDCA."
The TCA gives the FDA authority, which Brown & Williamson
suggests it previously lacked with regard to cigarettes, to regulate
e-cigarettes as "tobacco products." In 2009, Congress passed the
Family Smoking Prevention and Tobacco Control Act, informally
referred to as the Tobacco Control Act, which amended the Food,
Drug, and Cosmetic Act of 1938." The TCA's purpose is to give
the FDA authority to regulate tobacco products to address public
health concerns while continuing to permit the sale of tobacco to
83. See Alicia Gallegos, FDA Barred from Regulating E-Cigarettes as Medical Devices,
AM. MED. NEWS (Dec. 10, 2010), http://www.amednews.com/article/20101229/profession/31
2299996/8/.
84. 21 U.S.C. § 387a(a) (2012).
85. Id. § 321(rr) (2012).
86. Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, 123
Stat. 1776, 1781 (2009) (amending 21 U.S.C. § 301).
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informed consumers." The TCA specifically provides the FDA
with authority to regulate, but not ban, recreational tobacco
use-an authority Congress did not give to the FDA under the
FDCA." The TCA expressly states that "Federal and State gov-
ernments have lacked the legal and regulatory authority and re-
sources they need to comprehensively address the public health
and societal problems caused by the use of tobacco products."" In
defining "tobacco product" broadly, so as to include "any product
made or derived from tobacco" intended for human consumption,
Congress intended to comprehensively regulate both traditional
tobacco products, such as combustible cigarettes and smokeless
tobacco, as well as more novel, unforeseen tobacco products de-
rived from tobacco, such as e-cigarettes.9 o
Necessarily, the definitions of "tobacco product" under the TCA
and "drug" or "device" under the FDCA are irreconcilable." Con-
gress has expressly stated: "The term 'tobacco product' does not
mean an article that is a drug . . . a device ... or a combination
product ... [in the FDCA]."9 Further, Congress granted addition-
al regulatory powers to the FDA, including pre-market and post-
market requirements, to specifically fulfill the Act's larger pur-
pose to "address issues of particular concern . . . especially the use
of tobacco by young people and dependence on tobacco"-a pur-
pose not expressly stated in the FDCA because the FDCA is not
finely tailored, and therefore not well-suited, to address complex,
tobacco-specific issues." The purpose of the TCA, as the FDA has
conceded, is not to "move the definitional line between tobacco
products and drugs" as, again, Congress has determined that the
terms are mutually exclusive.94 E-cigarettes fall squarely in the
more recent tobacco-tailored regulatory scheme of the TCA, not
the FDCA.
87. 21 U.S.C. § 387a note (Purpose subsec. 1, 6).
88. Id. § 387g(d)(3) (2012).
89. Id. § 387 note (2012) (Findings subsec. 7) (emphasis added).
90. Id. § 321(rr)(1) (2012) (emphasis added).
91. See Smoking Everywhere, Inc. v. FDA, 680 F. Supp. 2d 62, 66-67 n.4 (D.D.C.
2010).
92. 21 U.S.C. § 321(rr)(2).
93. Id. § 387 note (Purpose subsec. 2); see also id. (Findings subsec. 6-7, 14-15, 18);
id. § 387j(a)(2) (2012).
94. Smoking Everywhere, 680 F. Supp. 2d at 66-67 n.4; see 21 U.S.C. § 387a(c)(1)
(2012) ("Nothing in this subchapter ... shall be construed to affect, expand, or limit the
Secretary's authority over .. . products under this chapter [Tobacco Products].")
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In light of the FDA consistently recognizing that it lacked
FDCA regulatory authority over tobacco products until 1996, the
TCA can be read to fill a regulatory gap in the FDCA: the FDCA
does not apply to tobacco products that do not claim a therapeutic
benefit, and, therefore, the FDA could not regulate those products
prior to the TCA's enactment." Only recently, starting with a
1996 federal regulation leading to the Supreme Court's landmark
decision in FDA v. Brown & Williamson Tobacco Corp., has the
FDA attempted to regulate tobacco products under the FDCA."
Each time the FDA has attempted to regulate tobacco products
under the FDCA, the courts have made clear such regulation does
not fit within the FDCA's regulatory scheme." Congress, through
the TCA, made abundantly clear that the FDA's regulatory juris-
diction over tobacco products is entirely distinct from its preexist-
ing jurisdiction over drugs, devices, and combination products.
The TCA provides the FDA all the authority Congress deemed
appropriate to combat the public health and other issues present-
ed by tobacco products-and ample authority to do so. The TCA is
well-equipped to regulate the e-cigarette industry with a more le-
nient regulatory scheme, when compared to the stringent FDCA,
which will ensure e-cigarettes remain available to users while en-
suring a basic level of safety." This balance is especially im-
portant to former heavy smokers seeking to avoid the harmful
health effects of chronic tobacco use by replacing tobacco ciga-
rettes with e-cigarettes." While opponents of e-cigarettes claim
95. See 21 U.S.C. § 387a(a).
96. FDA v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 126 (2000); Regulations
Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect
Children and Adolescents, 61 Fed. Reg. 44,396, 44,418 (Aug. 28, 1996) (to be codified at 21
C.F.R. pts. 801, 803, 804, 807, 820, 897).
97. See, e.g., Brown & Williamson, 529 U.S. at 126; Sottera, Inc. v. FDA, 627 F.3d 891,
898-99 (D.C. Cir. 2010).
98. The TCA does not allow the FDA to outright ban cigarettes or to require cigarette
manufactures to reduce nicotine levels to zero. 21 U.S.C. § 387g(d)(3)(A) (2012) (prohibit-
ing banning all cigarettes); id. § 387g(d)(3)(B) (prohibiting reducing the nicotine yield in
tobacco products to zero); see infra, Part III.B.2.
99. An Electronic Cigarette Ban: What Would Users Do?, SMOKERS ANGEL,
http://www.ecigarettedirect.co.uk/research/ecig-user-survey/results. html (last visited Apr.
14, 2014) (finding that 67.8% of e-cigarette users in the UK "completely replaced tobacco
cigarettes with electronic cigarettes"); David Wenner, Could E-Cigarettes Be the Solution
You Need to Quit Smoking?, PENN LIVE (Feb. 11, 2014, 11:45 AM), http://www.pennlive.
com/midstate/index.ssfl2014/02/electronic-cigarettese-cigarel.html (referencing the re-
search of a Penn State scientist specializing in tobacco addiction and finding that e-




that the nicotine in e-cigarettes has serious adverse health conse-
quences, nicotine, often found in combustible cigarettes at much
higher dosages than e-cigarettes, may not be that harmful.
2. Nicotine's Health Effects and Its Classification as a "Tobacco
Product" Under the TCA
"Nicotine," to the general public, often carries a negative conno-
tation, but this impression of the substance is usually unfounded.
Nicotine is a colorless or pale yellow, oily liquid found in tobacco
and related plants such as potatoes and tomatoes.100 Although
nicotine is an addictive substance, some scientists claim it is not
especially hazardous in itself."0 ' Although the FDA is incredibly
cautious when addressing nicotine, the UK Medicines and
Healthcare Products Regulatory Agency has stated that "nico-
tine . . . is not a significant risk factor for cardiovascular events,
and does not cause cancer or respiratory disease."'0 2 The FDA's
cautiousness seems to rest largely on skepticism and negative as-
sociation: cigarettes are bad for your health and nicotine is in cig-
arettes. Ironically, it is difficult to find studies claiming nicotine
is harmful to human health, in and of itself, whereas it is rela-
tively easy to find many sources affirming that nicotine is actual-
ly not inherently harmful and instead is similar to other popular
drugs such as caffeine.' Therefore, this FDA skepticism and
over-cautiousness is misplaced.
The fact that e-cigarettes almost solely contain nicotine sup-
ports the argument that e-cigarettes are inherently less danger-
ous than combustible cigarettes, which are filled with various
chemicals. Traditional, combustible cigarettes contain not only
nicotine, but also numerous carcinogens and various other chemi-
100. Edward F. Domino et al., The Nicotine Content of Common Vegetables, 329 NEW
ENG. J. MED. 437, 437 tbl.1 (1993), available at http://www.nejm.org/doilfull/10.1056/NEJ
M199308053290619?keytype2=tf ipsecsha&ijkey-09174147c440b96900667f3fef93fd3cd01
00cee&&.
101. See Britton, supra note 18.
102. MEDS. & HEALTHCARE PRODS. REGULATORY AGENCY, MHRA PUBLIC ASSESSMENT
REPORT: THE USE OF NICOTINE REPLACEMENT THERAPY TO REDUCE HARM IN SMOKERS 4
(2010), available at http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresource
s/con065622.pdf.
103. See, e.g., Univ. of Alberta Med. School, Dep't of Pub. Health Sci., All About Nico-
tine (And Addiction), TOBACCO HARM REDUCTION, http://www.tobaccoharmreduction.
org/faq/nicotine.htm (last visited Apr. 14, 2014).
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cals not found in e-cigarettes. 4 Over the past couple decades, the
FDA has funded several committees and studies to address nico-
tine science and policy issues.o' These committees include the
Committee to Assess the Science Base for Tobacco Harm Reduc-
tion, which wrote the 2001 report Clearing the Smoke: Assessing
the Science Base for Tobacco Harm Reduction, and the Committee
on Scientific Standards for Studies on Modified Risk Tobacco
Products, which wrote the 2012 report Scientific Standards for
Studies on Modified Risk Tobacco Products.'6 Aside from general
conclusions regarding combustible cigarettes' adverse health ef-
fects, both studies endorsed modified risk tobacco products, prod-
ucts marketed with a claim to reduce harm or the risk of tobacco-
related disease,o' and nicotine replacement products, such as the
nicotine patch and gum.'" Although Clearing the Smoke was pub-
lished before e-cigarettes were marketed in the United States, the
study still portrays products that have less combustion than com-
bustible cigarettes, like e-cigarettes, as a less risky alternative."o
The Scientific Standards for Studies on Modified Risk Tobacco
Products report, released after e-cigarettes were marketed in the
United States, acknowledged that scientists have found that e-
cigarettes do, indeed, "hold promise for harm reduction."o10 In
104. See Caponnetto et al., supra note 2, at 14.
105. See, e.g., Brady Dennis, FDA Backs Low-Nicotine Cigarette Research as It Weighs
New Regulatory Power, WASH. POsT (July 30, 2013), http://www.washingtonpost.com/na
tionallhealth-science/fda-tests-low-nicotine-cigarettes-as-it-weighs-new-regulatory-power
/2013/07/30/122cO954-efbd-11e2-9008-61e94a7ea20d.story.html; Elizabeth Fernandez,
UCSF Awarded $20M Federal Grant on Tobacco Regulatory Sciences, UCSF (Sept. 13,
2013), http://www.ucsf.edu/news/2013/09/108946/ucsf-awarded-20m-federal-grant-tobacco-
regulatory-sciences; see also Federal Overview: Poor Results in 2013, AM. LUNG ASS'N,
STATE OF TOBACCO CONTROL, http://www.stateoftobaccocontrol.orglat-a-glance/federal-gov
ernment/ (last visited Apr. 14, 2014) (referencing the FDA's 2013 report which found that
menthol in cigarettes is more likely to lead to new users, primarily youth).
106. KATHLEEN STRATTON ET. AL., INST. OF MED., COMM. TO ASSESS THE Sol. BASE FOR
TOBACCO HARM REDUCTION, CLEARING THE SMOKE: ASSESSING THE SCIENCE BASE FOR
TOBACCO HARM REDUCTION (2001), available at http://books.nap.edu/openbook.php?record
id=10029; COMM. ON SCIENTIFIC STANDARDS FOR STUDIES ON MODIFIED RISK TOBACCO
PRODS., SCIENTIFIC STANDARDS FOR STUDIES ON MODIFIED RISK TOBACCO PRODUCTS,
(2012), available at http://books.nap.edu/openbook.php?recordid=13294.
107. Tobacco Products: Modified Risk Tobacco Products, FOOD & DRUG ADMIN., http://
www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297747
(last updated June 14, 2013). Congress made clear that these modified risk products "shall
be regulated" under the TCA "and shall not be subject to the [drug/device provisions of the
FDCA]." 21 U.S.C. §§ 387a(a), 387k (2012).
108. See STRATTON ETAL., supra note 106, at 4-5 & tbl.1.
109. See id. at 5.
110. See SCIENTIFIC STANDARDS FOR STUDIES ON MODIFIED RISK TOBACCO PRODUCTS,
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sum, these two FDA-funded studies concluded, either directly or
inferentially, that e-cigarettes can be a powerful tool in reducing
tobacco-related disease and, therefore, should remain available to
consumers absent compelling evidence that they are harmful.
Evidence that nicotine is not particularly harmful is fairly
abundant even outside of U.S.-funded studies. The Royal College
of Physicians ("RCP") is a UK-based organization that produces
reports similar to those published by the U.S. Surgeon General
and has been at the forefront of tobacco policy since 1962."' In
2007, the RCP published Harm Reduction in Nicotine Addiction:
Helping People Who Can't Quit and made a case for "harm reduc-
tion strategies to protect smokers" which included using e-
cigarettes to fulfill nicotine cravings rather than combustible cig-
arettes."' The preface of the report makes the bold claim that
"smokers smoke predominantly for nicotine, that nicotine itself is
not especially hazardous, and that if nicotine could be provided in
a form that is acceptable and effective as a cigarette substitute,
millions of lives could be saved.""' In addition to its clear support
of nicotine addicts getting their nicotine from sources aside from
combustible cigarettes, the RCP report study also critiques nico-
tine regulatory structures in general: "[T]he regulatory systems
that currently govern nicotine products in most countries, includ-
ing the UK, actively discourage the development, marketing and
promotion of significantly safer nicotine products to smokers.""4
The two American groups and the RCP make clear that because
nicotine addiction is not going away anytime soon, it seems coun-
ter-intuitive to have drawn-out regulatory procedures and limit-
ing schemes that restrict access to e-cigarettes and other sources
of nicotine, while combustible cigarettes, which are regarded as
more dangerous, remain widely accessible throughout the United
States. Because of their reduced harm, when compared to com-
supra note 106, at 50.
111. See Jim Solyst, Toward a Comprehensive Policy on Nicotine Delivery Products and
Harm Reduction, 67 FOOD & DRUG L.J. 393, 395 (2012). See generally Smoking and Health
(1962), ROYAL COLL. OF PHYSICIANS, http://www.rcplondon.ac.uk/resources/smoking-and-
health-1962 (last visited Apr. 14, 2014) (chronicling the significance of a landmark 1962
report to "the RCP's enduring role in public health ... [and] five decades of action on to-
bacco control").
112. See Britton, supra note 18, at Preface, 183, 225-27 (arguing that harm reduction
strategies, such as vaping e-cigarettes instead of smoking combustible cigarettes, require
more supportive regulatory structures).
113. See id. at Preface.
114. See id.
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bustible cigarettes, the FDA should loosely regulate e-cigarettes,
as they have the potential to positively impact current combus-
tible cigarette smokers.
Although e-cigarettes do not contain any tobacco and do not
burn like "real cigarettes," they fall within the TCA's definition of
"tobacco products" because they contain nicotine derived from to-
bacco."' Simply put, e-cigarettes deliver nicotine that is derived
from tobacco to humans in vapor form."' Therefore, e-cigarettes
clearly meet the definition of a "tobacco product.""' Congress
omitted any reference to specific tobacco products in its broadly
worded definition of "tobacco product," which demonstrates that
by its definition of tobacco products, Congress likely intended to
include within that definition a broader range of products than
just traditional combustible cigarettes and anticipated that newly
developed products like e-cigarettes would also fall under TCA
regulation."' A "tobacco product," under the TCA, certainly en-
compasses e-cigarettes.
3. The FDA's Specific Authority Under the TCA
Although there are nicotine products on the market, such as
Nicoderm CQ gum, which are regulated by the FDA under the
FDCA, each of these FDCA-regulated products have an important
commonality: they make therapeutic claims."' Conversely, e-
cigarettes do not predominantly make such claims, and in turn
should be classified by the FDA as a tobacco product that cannot
be regulated under the FDCA."' Following the same logic in
Brown & Williamson: because e-cigarettes do not make therapeu-
tic claims, the FDA lacks jurisdiction to regulate e-cigarettes as a
drug/device combination.' 2' Hence, this regulatory gap for non-
therapeutic-claiming tobacco products, such as combustible ciga-
rettes, smokeless tobacco, and e-cigarettes, acted as a catalyst for
115. See 21 U.S.C. § 321(rr)(1) (2012).
116. See Demick, supra note 37.
117. See 21 U.S.C. § 321(rr)(1).
118. Id.
119. See, e.g., NICODERM CQ, http://www.nicodermcq.com (last visited Apr. 14, 2014)
(containing slogans such as "NOW, Quit on your own terms").
120. See, e.g., BLU CIGS, http://www.blucigs.com (last visited Apr. 14, 2014) (containing
slogans such as "freedom to have a cigarette without the guilt").
121. See FDA v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 126 (2000).
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the enactment of the TCA. 2 2 To be clear, while many of e-
cigarettes' benefits lie in the fact that they are a form of harm re-
duction, these claims are predominantly not manifested by the
manufacturers.1 23 Whereas products such as Nicoderm CQ are ex-
pressly advertised to stop smoking, e-cigarette manufacturers do
not make these claims. E-cigarette manufacturers' objective in-
tent when advertising is important, as at least one court has
looked at how manufacturers market their products-"'the objec-
tive intent of the persons legally responsible' for labeling the
product"-and determined that e-cigarettes are marketed not as
therapeutic devices, but as recreational alternatives to combus-
tible cigarettes.124 Because the FDCA is largely irrelevant to e-
cigarette regulation, the FDA's specific regulatory authority un-
der the TCA becomes quite relevant.
Under the TCA, and outside of the normal provisions of the
FDCA, the FDA has the authority to regulate tobacco products,
which are "any product[s] made or derived from tobacco . . . in-
tended for human consumption."125 The TCA (1) requires tobacco
companies to submit to the FDA information regarding their
products' ingredients and related research; 2 (2) creates an "adul-
terated tobacco products" category, which allows the FDA to im-
pose manufacturing standards,2 7 and creates a "misbranded to-
bacco products" category, which subjects tobacco packaging to
strict labeling requirements;128 (3) allows the FDA to regulate to-
bacco advertising and marketing, while also eliminating most fla-
voring additives in cigarettes that are designed to appeal to
youths;129 (4) allows the FDA to regulate nicotine yields;2 0 (5) es-
tablishes provisions for regulating "modified risk tobacco prod-
ucts;"' (6) requires pre-market approval for new tobacco products
122. See 21 U.S.C. § 387 note (2012) (Findings subsec. 7).
123. See Smoking Everywhere, Inc. v. FDA, 680 F. Supp. 2d 62, 73 (D.D.C. 2010).
124. Id. (citing 21 C.F.R. § 201.128 (2013)).
125. 21 U.S.C. § 321(rr)(1) (2012). The TCA explicitly states that tobacco products shall
not be considered a drug, device, or combination product under the FDCA. Id. § 321(rr)(2).
Technically, the Center for Tobacco Products ("CTP') is responsible for enforcing the TCA,
but because the CTP is within the FDA I will continue to refer to the FDA as the enforce-
ment agency for the TCA. See id. § 387a(e) (2012).
126. Id. § 387d(a)(1), (4) (2012).
127. Id. § 387b (2012).
128. Id. § 387c (2012)
129. Id. § 387f(d)(1) (2012); id. § 387g(a)(1)(A) (2012).
130. Id. § 387g(a)(4)(A)(i).
131. Id. § 387k (2012).
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to determine their impact on the public health;'32 and (7) estab-
lishes a Tobacco Products Scientific Advisory Committee to pro-
pose regulations necessary to protect the public health."' Despite
these powerful regulatory tools, the FDA can neither ban tradi-
tional tobacco products nor can they require nicotine yields of to-
114bacco products to be reduced to zero.
More concisely, the TCA grants the FDA the authority to regu-
late ingredients, testing, development, manufacture, packaging,
labeling, advertising, distribution, sale, and health and safety
disclosures of tobacco products. While this list of authorities is
quite broad and powerful, it is especially necessary to provide
basic protection to the general public regarding combustible ciga-
rettes.' If the FDA were to fully utilize all of its regulatory au-
thority on e-cigarettes, it would be a grave mistake impeding the
development and distribution of a product that is immensely ben-
eficial to the smoking population, and the secondhand smoke-
breathing population, of the United States."' A looser regulatory
structure would ensure that e-cigarette manufacturers provide
accurate information regarding their nicotine cartridges and do
not target youth populations, while keeping the vaporizers avail-
able for those, mainly combustible cigarette smokers, who benefit
from and have come to rely on them.
B. The FDA Has No Ability to Regulate E-Cigarettes Under the
FDCA
The FDA first attempted to regulate e-cigarettes in 2010 under
its FDCA "authority" and was quickly corrected by the United
States Court of Appeals for the D.C. Circuit. Applying the reason-
ing from the Supreme Court's landmark decision in Brown & Wil-
liamson, the court reminded the FDA that it cannot regulate to-
132. Id. § 387j (2012). A new tobacco product can avoid the pre-market review process
if the manufacturer can show it is "substantially equivalent" to another commercially
marketed product on the market as of February 15, 2007. Id. § 387e(j) (2012).
133. Id. § 387q (2012).
134. Id. § 387g(d)(3)(A) (prohibiting banning); id. § 387g(d)(3)(B) (prohibiting reducing
nicotine yields to zero).
135. See HEALTH CONSEQUENCES OF SMOKING, supra note 4, at 861.
136. See id.; Health Effects of Secondhand Smoke, CTRS. FOR DISEASE CONTROL &
PREVENTION, http://www.cdc.gov/tobacco/data_statistics/factLsheets/secondhand-smoke/he
altheffects/ (last visited Apr. 14, 2014) (citing secondhand smoke as causing health prob-




bacco products, which claim no therapeutic benefits for their us-
ers, under the FDCA.m3 In fact, if the FDA had the authority to
regulate cigarettes and related products under the FDCA, the
statute would require the products to be banned."' Congress did
not intend for these products to be banned, which Congress made
clear in the TCA, while also expressly stating that the FDA can-
not require manufacturers to reduce nicotine yields to zero.'" The
FDCA is not tailored to the specific issues that tobacco products
raise, such as their effect on younger populations. The TCA is tai-
lored to these specific issues. The FDA should focus its time and
efforts on implementing an effective, albeit minimalist, regulato-
ry structure under the TCA rather than waste more time aggres-
sively trying to force a square peg into a round hole by attempting
to use the FDCA to regulate e-cigarettes.
1. Sottera, Smoking Everywhere, and Therapeutic Products
In Sottera, Inc. v. FDA, the D.C. Circuit properly prevented the
FDA's attempt to block e-cigarette imports under the FDCA, and
other courts likely will block future, similar attempts as well if e-
cigarette manufacturers continue to market their products as a
recreational alternative to combustible cigarettes. Although Con-
gress passed the TCA in 2009, after e-cigarettes were prominent-
ly marketed in the United States, the FDA continued its attempts
to regulate tobacco products, including e-cigarettes, under the
FDCA. In Sottera, the FDA denied the entry of certain e-
cigarettes-imported and distributed by NJOY-into the United
States under a drug/device provision of the FDCA.140 Co-party
Smoking Everywhere, another importer and distributer of e-
cigarettes, moved for a preliminary injunction, arguing that the
FDA can regulate e-cigarettes under the TCA, but not the
FDCA.14' More specifically, Smoking Everywhere argued that the
Supreme Court's decision in FDA v. Brown & Williamson Tobacco
Corp. gave the FDA authority under the FDCA only if e-
cigarettes claimed a therapeutic effect, which they do not.142 The
court made short work of the case, holding that the FDA cannot
137. Sottera, Inc. v. FDA, 627 F.3d 891, 893, 899 (D.C. Cir. 2010).
138. Smoking Everywhere, Inc. v. FDA, 680 F. Supp. 2d 62, 70 (D.D.C. 2010).
139. 21 U.S.C. § 387g(d)(3)(B).
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regulate "customarily marketed" tobacco products under the
FDCA drug/devices provisions.14
While the FDA asserted that "nicotine is a drug" under the
FDCA, and therefore subject to regulation under the FDCA re-
gardless of whether the manufacturer made therapeutic claims,
the court clarified that Congress enacted the TCA to fill the regu-
latory gap regarding tobacco products in the FDCA.144 Specifically,
the TCA broadly defines a tobacco product as "any product made
or derived from tobacco" and "does not mean an article that is a
drug under [the FDCA's drug provision]." 145 Further, the court
reasoned, the TCA does not "affect, expand, or limit" the FDA's
drug/device authority under the FDCA.14 ' Any product subject to
TCA regulation cannot simultaneously be subject to drug or de-
vice classification under the FDCA.'47 It would be difficult for a
statute to be clearer: the FDCA cannot be used to regulate tobac-
co products not claiming a therapeutic benefit.148
In Smoking Everywhere, Inc. v. FDA the U.S. District Court for
the District of Columbia emphasized that e-cigarettes, as ordinar-
ily marketed, do not claim therapeutic benefits for their users,
and, therefore, the FDA cannot regulate e-cigarettes under the
FDCA.'49 The petitioners in Sottera argued that their e-cigarettes
were "marketed and labeled for 'smoking pleasure,' not as a
therapeutic product.' While the FDA in Sottera ultimately did
143. Id. at 898.
144. Id. at 894; see 21 U.S.C. § 321(g)(1)(C) (2012) (defining drug as an article that
affects the structure or function of the body); Regulations Restricting the Sale and Distri-
bution of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents, 61 Fed.
Reg. 44,396, 44,400 (Aug. 28, 1996) (to be codified at 21 C.F.R. pts. 801, 803, 804, 807, 820,
897) (claiming cigarettes and smokeless tobacco fall under FDA regulatory authority with-
out mention of therapeutic claims).
145. 21 U.S.C. § 321(rr)(1)-(2). A better reading of this section may be "that products
made or derived from tobacco that are marketed for therapeutic purposes are not 'tobacco
products' within the meaning of the Tobacco Control Act, and are therefore subject to regu-
lation under the ... FDCA." Sottera, 627 F.3d at 903 (Garland, J. concurring) (emphasis
added).
146. 21 U.S.C. § 387a(c)(1) (2012).
147. Id. § 321(rr)(2).
148. Rather than exercise its undisputed jurisdiction to regulate e-cigarettes under the
TCA, the FDA has spent more than a year litigating its right to regulate e-cigarettes un-
der a statute not intended to authorize the regulation of customarily marketed tobacco
products.
149. See Smoking Everywhere, Inc. v. FDA, 680 F. Supp. 2d 62, 75, 78 (D.D.C. 2010).
150. Sottera, 627 F.3d at 893. In fact, Congress seemed to believe that tobacco products
in general do not make therapeutic claims (as defined by the FDCA) because the TCA pro-
vides the FDA authority over tobacco products without requiring therapeutic claims. See §
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not contest the e-cigarette manufacturer's claim that its products
are not marketed for therapeutic use, the trial court discussed the
issue in more detail in a prior action that was later consolidat-
ed."" In Smoking Everywhere, the court held that the FDA had no
authority to treat e-cigarettes as drug-device combination under
the FDCA when they only purport to offer consumers the same
recreational effect as a combustible cigarette.'5 2 According to the
court, the fact that e-cigarettes may be used by consumers as a
way to treat nicotine addiction without turning to combustible
cigarettes did not require e-cigarettes to be classified as a thera-
peutic product."' The court made clear that "the 'intended use' of
a product is determined by 'the objective intent of the persons le-
gally responsible' for labeling the product."'" Here, the court
found that the FDA's claim was unsupported by the required
"substantial evidence" that Smoking Everywhere objectively in-
tended to market its products as therapeutic."'
In fact, e-cigarette manufacturers likely want the exact oppo-
site of smoking cessation. The FDA's claim that e-cigarettes, like
those in Smoking Everywhere, are objectively intended to "pre-
vent, mitigate, or treat the withdrawal symptoms of nicotine ad-
diction" runs counter to the foundational business model of e-
cigarettes: keep people addicted to nicotine while eliminating the
other harmful additives found in combustible cigarettes.'"' An ob-
vious, likely valid, assumption is that e-cigarette companies want
to encourage rather than "prevent, mitigate, or treat" nicotine
use."' If e-cigarettes are marketed as simply an alternative to
combustible cigarettes, it is difficult, if not impossible, for the
FDA to meet its burden to show that e-cigarettes are objectively
intended to treat nicotine addiction and withdrawal. 15  Per the
321(rr)(1) (making no reference to therapeutic-claiming tobacco products).
151. Sottera, 627 F.3d at 898-99; see Smoking Everywhere, 680 F. Supp. 2d at 73-75.
152. Smoking Everywhere, 680 F. Supp. 2d at 73-74.
153. Id. at 73-75.
154. Id. at 73; see 21 C.F.R. § 201.128 (2013) (defining intended use of a product by
looking at "the objective intent of the persons legally responsible for" labeling the product).
It should be noted that the regulation cited refers to products that are drugs, which e-
cigarettes are not, but a similar labeling standard under the TCA may be applied to re-
quire e-cigarette manufacturers to make clear on their packaging that their product is not
intended for a therapeutic use, but instead for recreational use. Id.
155. Smoking Everywhere, 680 F. Supp. 2d at 73.
156. Id. (internal quotation marks omitted). The company name itself, "Smoking Eve-
rywhere," likely illustrates the company's intent as well.
157. Id. at 74.
158. Id. at 73. If e-cigarette manufacturers did change their current marketing strate-
13452014]
UNIVERSITY OF RICHMOND LAW REVIEW
court's decision, e-cigarettes are marketed and intended as recre-
ational smoking devices and, thus, cannot be regulated under the
FDCA."5
Although tobacco products making express therapeutic claims
properly fall within the FDA's jurisdictional authority under the
drug/devices provisions of the FDCA, e-cigarette manufacturers
do not make these therapeutic claims. As of now, e-cigarettes
manufacturers not making therapeutic claims remain outside the
scope of the FDCA. A look at the University Medical and Dental
School of New Jersey's webpage, which organizes a large collec-
tion of cigarette and tobacco advertising, reveals that several e-
cigarette advertisements feature the product's ability to be
smoked anywhere, leave no adverse smell, allow a user to inhale
no tar or smoke, and mitigate social stigma.160 These types of ad-
vertisements hardly portray e-cigarettes as "therapeutic" in a
broad sense of the word, let alone within the narrowed meaning
of "therapeutic" defined by the FDCA."' To avoid confusion about
what constitutes an "objective intent" to market e-cigarettes as
therapeutic, and therefore triggers regulation under the stricter
FDCA, the FDA should issue a guidance document directed at the
e-cigarette industry clarifying or giving examples of what is and
is not a therapeutic claim.
2. Brown & Williamson and the Absurd Result of Regulating E-
Cigarettes Under the FDCA
Finally, the FDA's contention in Sottera and Smoking Every-
where that nicotine is a drug, is excluded from the definition of
"tobacco product," and therefore can be regulated under the
FDCA produces an absurd result Congress most likely did not in-
tend.'62 As discussed in the Supreme Court's decision in Brown &
gies and began advertising their products as therapeutic, then FDCA regulation is more
viable.
159. Id. at 74 n.15 (noting an express disclaimer on the packaging that the product is
not a smoking cessation device).
160. Trinkets & Trash: Artifacts of the Tobacco Epidemic, RUTGERS SCH. OF PUB.
HEALTH, http://trinketsandtrash.org (last visited Apr. 14, 2014) (using the "Category" box,
search for "E -cigarettes").
161. See 21 C.F.R. § 3.2 (2013) (defining, within another definition, "'therapeutic' action
or effect [to] include[| any effect or action . .. intended to diagnose, cure, mitigate, treat, or
prevent disease, or affect the structure or any function of the body").
162. Smoking Everywhere, 680 F. Supp. 2d at 70, 75.
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Williamson, if the FDA had authority to regulate cigarettes and
smokeless tobacco under the FDCA, then the FDA would effec-
tively be required to ban them."' Because the FDA has repeatedly
found that "tobacco products" are "unsafe," "dangerous," and that
"[t]obacco alone kills more people each year in the United States
than acquired immunodeficiency syndrome (AIDS), car accidents,
alcohol, homicides, illegal drugs, suicides, and fires, combined,"
tobacco products would necessarily be immediately removed from
the market.'64 Importantly, the FDCA allows the FDA to forbid
the introduction of "any food, drug, device, tobacco product, or
cosmetic that is adulterated or misbranded," and defines a mis-
branded drug or device as one "dangerous to health when used in
the dosage or manner . .. suggested in the labeling.""' Therefore,
given the FDA's conclusion that tobacco is dangerous and unsafe,
the FDCA likely would require the FDA to ban tobacco products
as "misbranded" drugs. Further, there is no viable option availa-
ble after tobacco products are labeled misbranded as there are no
labeling options that provide "adequate directions for use .. . nec-
essary for the protection of users" because use, in and of itself,
endangers and harms users.'6 6 These labeling problems are
somewhat expected given that e-cigarettes are not intended to
treat nicotine addiction; instead they simply provide a less risky,
recreational alternative to combustible cigarettes that already
"endanger" their users.
Additionally, section 360c(a) of the FDCA requires the FDA to
place regulated devices into one of three classifications based on a
"reasonable assurance of safety and effectiveness."'6 7 While the
FDA has not classified tobacco products under the FDCA (be-
cause they do not have the authority to regulate them under the
FDCA), it is safe to assume that they would be placed in Class III
because they "present[] a potential unreasonable risk of illness or
injury" based on the FDA's prior findings regarding tobacco.6 As
a Class III device, tobacco products would be subject to pre-
163. FDA v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 137 (2000).
164. Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless
Tobacco to Protect Children and Adolescents, 61 Fed. Reg. 44,396, 44,398 (Aug. 28, 1996).
165. 21 U.S.C. § 331(a) (2012); id. § 352(j) (2012).
166. Id. § 352(f).
167. Id. § 360c(a)(1)(A)-(C) (2012).
168. Id. § 360c(a)(1)(C)(ii); see Regulations Restricting the Sale and Distribution of Cig-
arettes and Smokeless Tobacco to Protect Children and Adolescents, 61 Fed. Reg. at
44,398.
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market approval, which requires a "showing of reasonable assur-
ance that such device is safe under the conditions of use pre-
scribed, recommended, or suggested in the proposed labeling
thereof.""' The language "safe under the conditions of use pre-
scribed" is directed at drugs and devices intended to treat various
health conditions or products making therapeutic claims, hence,
when applied to e-cigarettes the result is nonsensical because e-
cigarettes do not treat a health condition nor do they make thera-
peutic claims."'o Further, viewing these provisions in parallel with
the TCA leads to a direct conflict. Section 387g of the TCA ex-
pressly prohibits the FDA from "requiring the reduction of nico-
tine yields of a tobacco product to zero" which, if e-cigarettes were
regulated under the FDCA, would be the result."' Again, there
does not seem to be a feasible way for the FDA to make a finding
of "reasonable safety" in regard to tobacco products based on their
past findings of dangerousness."'
The convoluted, cumbersome nature of regulating tobacco
products under the FDCA may be one of the reasons Congress
enacted an entire tobacco-specific statute, the TCA, to begin with.
Reviewing the relevant substantive provisions of the FDCA
demonstrates that the FDCA's drug/device regulation focuses on
items intended to benefit public health-the focus is not on prod-
ucts like e-cigarettes that lack a therapeutic purpose. The FDCA
is not a regulatory option for the FDA, and instead of making ad-
ditional repackaged arguments under the statute that courts like
the Smoking Everywhere court will inevitably reject, the FDA
should focus its regulatory efforts where they are properly re-
ceived: under the TCA, using a minimalist scheme to regulate
basic product safety while keeping e-cigarettes available to those
who use, and often rely, on them."'
169. 21 U.S.C. § 360e(d)(2)(A) (2012).
170. Id. § 360e(a)(1)(C)(ii); see Sottera, Inc. v. FDA, 627 F.3d 891, 898 (D.C. Cir. 2010);
Smoking Everywhere, Inc. v. FDA, 680 F. Supp. 2d 62, 73 (D.D.C. 2010).
171. 21 U.S.C. § 387g(d)(3) (2012).
172. See Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless
Tobacco to Protect Children and Adolescents, 61 Fed. Reg. at 44,412 (specifically using the
phrase "reasonable assurance that the device is safe").
173. Jordan Paradise, No Sisyphean Task: How the FDA Can Regulate Electronic Ciga-
rettes, 13 YALE J. HEALTH POL'Y L. & ETHICS 326, 362, 369, 371, 374 (2013). The FDA has
already been chastised for "ironically, notwithstanding that Congress has now taken the
unprecedented step of granting FDA jurisdiction over [tobacco] products, . . . remain[ing]
undeterred." Smoking Everywhere, 680 F. Supp. 2d at 78.
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IV. A MINIMALIST FEDERAL REGULATORY SCHEME IS MOST
BENEFICIAL TO THE PUBLIC
E-cigarettes need to be available to the public, where they can
be incredibly effective at reducing the enormous, adverse impact
that smoking combustible cigarettes has on human health, in-
stead of caught up in a regulatory web that likely will take years
to be formally approved." 4 The Center for Disease Control has
made clear that "[i]n both 2010 and 2011, e-cigarette use was sig-
nificantly higher among current smokers compared to both former
and never smokers.""' This supports the idea that e-cigarettes are
not primarily attracting non-smokers, but instead are providing
an alternative to those who smoke combustible cigarettes. This
Part argues that the FDA should utilize its TCA authority to reg-
ulate e-cigarettes in the most efficient manner to ensure that they
remain available to consumers that want to use them while
providing a basic threshold of safety. A British study of smoking
reductions over the past fifty years attributes a large amount of
the success in cutting back to political leadership with "a prag-
matic willingness to apply measures that are likely to work in the
public interest.""' A minimalist regulatory scheme would illus-
trate the FDA's pragmatic willingness to work in favor of the pub-
lic interest, not against it.
The minimalist regulatory regime proposed in this Part is cen-
tered on the fact that "if we get all tobacco smokers to switch from
regular cigarettes (to electronic cigarettes), we would eventually
reduce the US death toll from more than 400,000 a year to less
than 4,000, maybe as low as 400."'" In a recent study, the RCP
predicts that the "[m]arket could be opened to a new generation of
innovative nicotine products that will provide smokers with an
opportunity to choose an effective low-hazard alternative that is
174. Even the Center for Disease Control concedes that e-cigarettes "appear to have far
fewer of the toxins found in smoke compared to traditional cigarettes." About One in Five
U.S. Adult Cigarette Smokers Have Tried an Electronic Cigarette, CTRS. FOR DISEASE
CONTROL & PREVENTION, http://www.cdc.gov/medialreleases/2013/p0228_electronic-cigare
ttes.html (last visited Apr. 14, 2014).
175. Id. (emphasis added).
176. ROYAL COLL. OF PHYSICIANS, FIFTY YEARS SINCE SMOKING AND HEALTH:
PROGRESS, LESSONS AND PRIORITIES FOR A SMOKE-FREE UK 54 (2012) [hereinafter FIrrY
YEARS], available at http://www.rcplondon.ac.uk/sites/default/files/fifty-years-smoking-hea
lth.pdf.
177. New Year's Resolution, supra note 29.
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attractive and competitive with cigarettes at the point of sale.""'
However, overregulation of a product that does not need it would
make these options virtually non-existent for smokers today. E-
cigarettes have many advantages over combustible cigarettes and
by creating a minimalist regulatory scheme under the TCA that
regulates advertising, labeling requirements, and general product
standards involving safety and proper function, these advanta-
geous products can remain available on the market to help poten-
tially reduce the U.S. tobacco-related death toll.
A. The Advantages of E-Cigarettes over Combustible Cigarettes
and Other Tobacco Products
While e-cigarette manufacturers have received substantial crit-
icism for touting their product as a healthy alternative to tradi-
tional, combustible cigarettes, there is no dispute that e-
cigarettes simply do not contain many unhealthy components
that combustible cigarettes do contain. There is no real scientific
dispute over the fact that switching to vaping e-cigarettes instead
of smoking combustible cigarettes means users can avoid the
myriad of toxins and other carcinogens created by tobacco com-
bustion."' For example, e-cigarettes do not contain any carbon
monoxide.' Carbon monoxide, at low levels of exposure, such as
those present when a user smokes a combustible cigarette, causes
"headaches, dizziness, disorientation, nausea and fatigue."'
Likewise, e-cigarettes lack the vast number of chemical compo-
nents found in combustible cigarettes such as arsenic, formalde-
hyde, and vinyl chloride.'8 2 These chemicals, along with the other
178. See FIFIY YEARS, supra note 176, at 53-54.
179. Zachary Cahn & Michael Siegel, Electronic Cigarettes as a Harm Reduction Strat-
egy for Tobacco Control: A Step Forward or a Repeat of Past Mistakes?, 32 J. PUB. HEALTH.
POL'Y 16, 27-28 (2011) ("[E]lectronic cigarettes are a much safer alternative to tobacco
cigarettes.").
180. Andrea R. Vansickel et al., A Clinical Laboratory Model for Evaluating the Acute
Effects of Electronic "Cigarettes": Nicotine Delivery Profile and Cardiovascular and Subjec-
tive Effects, 19 CANCER EPIDEMIOLOGY, BIoMARKERs & PREVENTION 1945, 1945, 1952
(2010), available at http://cebp.aacrjournals.org/content/19/8/1945.full.pdf+html?sid=709
e3fee-2ccc-41e4-bb63-d9f303ae08f4.
181. An Introduction to Indoor Air Quality (ZAQ): Carbon Monoxide (CO), U.S. ENVTL.
PROT. AGENCY, http://www.epa.gov/iaq/co.html (last visited Apr. 14, 2014).
182. See Cahn & Siegel, supra note 179, at 18 (noting that the primary components of
e-cigarettes are propylene glycol, nicotine, and glycerin); Harms of Smoking and Health
Benefits of Quitting, NAT'L CANCER INST., http://www.cancer.gov/cancertopics/factsheet/
Tobacco/cessation (last visited Apr. 14, 2014).
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250 harmful chemicals in tobacco smoke can cause health risks
such as cancer, heart disease, stroke, and asthma."' The danger-
ous chemicals listed above simply are not found in e-cigarettes
and therefore pose no risk to e-cigarette users.
Further, e-cigarettes can serve as a valuable harm reduction
device-one that can reduce tobacco-related death and disease
much more rapidly than a reduction of nicotine use. 84 E-
cigarettes have the potential to be more effective at moving
smokers away from traditional cigarettes than traditional nico-
tine reduction devices, such as the nicotine patch or nicotine gum,
because e-cigarettes provide the nicotine as well as simulate the
physical act of smoking, creating a psychological placebo effect in-
creasing the rate of cigarette abstinence.8 ' The tactile feel of an e-
cigarette, and the hand-to-mouth action of vaping one, has a
physiological and psychological impact on users, albeit to a lesser
degree than combustible cigarettes, that mimics the effects of in-
gesting nicotine. "' Studies have also shown that nearly half of
vapers using e-cigarettes as a smoking cessation tool stopped
smoking combustible cigarettes as a result of using an e-
cigarette.
Seeing that e-cigarettes expose users to less of the harmful
chemicals in cigarettes and carcinogens in cigarette smoke, the
FDA's concerns about greater potential public harm resulting
from e-cigarettes are entirely speculative. The FDA has acknowl-
edged that there is little scientific data addressing the health
risks of e-cigarettes because they have been subject to little test-
ing and analysis, making the long-term health consequences un-
known."' While there are scattered scientific opinions asserting
that nicotine and potential contaminants in e-cigarettes pose
risks to smokers because nicotine itself is addictive and potential-
ly harmful in high doses, the FDA's own analysis of e-cigarettes
183. Harms of Smoking and Health Benefits of Quitting, supra note 182.
184. David Sweanor et al., Tobacco Harm Reduction: How Rational Public Policy Could
Transform a Pandemic, 18 INT'L J. DRUG POL'Y 70, 74 (2006), available at http://www.sci
encedirect.com/science/article/piilS0955395906002416.
185. See Cahn & Siegel, supra note 179, at 22-23, 26; Caponnetto et al., supra note 2,
at 16.
186. See Caponnetto et al., supra note 2, at 16.
187. Michael B. Siegel et al., Electronic Cigarettes as a Smoking-Cessation Tool: Results
from an Online Survey, 40 AM. J. PREVENTIVE MED. 472, 472 (2011).
188. See Electronic Cigarettes, supra note 48.
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undermines these opinions. 89 The amount of nicotine in e-
cigarettes is often'90 comparable to the amount of nicotine in com-
bustible cigarettes, but, as previously discussed, nicotine itself is
not harmful."'9
The amount of nicotine in e-cigarettes found in the FDA study
was considerably lower than the amount of nicotine in combus-
tible cigarettes."' The study detected "[t]obacco specific nitrosa-
mines and tobacco specific impurities ["TSI"]," but at "very low
levels.""' If the FDA removed e-cigarettes from the market due to
their TSI levels, their reasoning would be circular and they would
waste time approving a constituent-TSI-that has already been
approved at equal levels as those found in e-cigarettes. 1 That
said, the levels of nicotine and TSIs found in e-cigarettes, by the
FDA itself, can hardly amount to a significant public danger that
the FDA needs to address by unleashing its full regulatory pow-
ers under the TCA. Writer Jacob Sullum aptly summarizes the
argument for limited federal government regulation of e-
cigarettes: "[R]egulations will restrict information about and ac-
cess to a potentially lifesaving product, thereby increasing smok-
ing-related illness and death in the name of public health and
consumer protection."" This potential result is clearly contrary to
the FDA's primary purpose to protect public health and can easily
189. Memorandum from B.J. Westenberger, Deputy Dir., CDER/OPS/OTR, Div. of
Pharmaceutical Analysis, to Michael Levy, Supervisor Regulatory Counsel, CDER, Office
of Compliance, Div. of New Drugs & Labeling Compliance (May 4, 2009) [hereinafter
Westenberger Study] (emphasis added), available at http://www.fda.gov/downloads/drugs/
scienceresearch/ucml73250.pdf ("Tobacco specific nitrosamines and tobacco specific impu-
rities were detected in both products at very low levels"); see also Cahn & Siegel, supra
note 179, at 18 (stating that the amount of tobacco-specific nitrosamines, a tobacco con-
taminant "is orders of magnitude lower than TSNA levels in regular cigarettes").
190. "Often" is used because some e-cigarettes that have been tested provided more
nicotine than what the product was labeled to deliver; this can be solved using the later
described minimalist regulatory scheme's focus on product standards. See infra Part
IV.B.2.
191. See Cahn & Siegel, supra note 179, at 22; see also infra Part II.A.2.
192. See Cahn & Siegel, supra note 179, at 22; Westenberger Study, supra note 189, at
2-3.
193. Westenberger Study, supra note 189, at 1.
194. Riccardo Polosa et al., A Fresh Look at Tobacco Harm Reduction: The Case for the
Electronic Cigarette, HARM REDUCTION J., Oct. 2013, at 1, 4, available at http://www.
harmreductionjournal.com/content/pdf/1477-7517-10-19.pdf ("[Tihis amount [of TSI] is
equal to the quantity reported to be present in a nicotine medicinal patch."); see also Cahn
& Siegel, supra note 179, at 18 ("[W]e already have more comprehensive knowledge of the
chemical constituents of electronic cigarettes than tobacco ones.").




be avoided through a loose regulatory scheme promulgated under
the TCA.
B. Where the FDA Should Focus Its TCA Regulatory Authority
over E-Cigarettes
Pursuant to its TCA authority, the federal government should
issue guidelines for the categories listed in this section that e-
cigarette manufacturers would be required to abide by when
promoting and developing their products. These guidelines, as de-
tailed in each respective section, should aim to maintain a bal-
ance between keeping the majority of e-cigarettes on the market
and preventing advertising and sale to minors. By leaving most e-
cigarettes on the market while only removing those that clearly
have adverse health risks, e-cigarette users will be able to con-
tinue reaping the benefits of vaping an e-cigarette over smoking a
combustible cigarette or using any other tobacco product.
1. Advertising and Sale to Minors
If the FDA is concerned that e-cigarettes are being marketed to
minors, the TCA ensures that the FDA "has the authority to ad-
dress ... the use of tobacco by young people."" Though the FDA
has not explicitly regulated e-cigarette advertising through the
TCA, it would be wise to include e-cigarette advertising with
combustible cigarettes under the statute because the advertising
and promotion concerns with both products are identical: warning
the public about the hazards of smoking and "protect[ing] the
public ... from being inundated with images of cigarette smoking
in advertising.""m By regulating e-cigarettes in the same manner
as combustible cigarettes, the FDA should prevent television, in-
ternet, radio, and billboard advertisements for e-cigarettes, all of
which are "advertising and promotion of the tobacco product.""
However, e-cigarette advertisements should be available at the
point of sale wherever combustible cigarettes can be purchased in
order to present a potentially lower-risk alternative.
196. Family Smoking Prevention and Tobacco Control Act, Pub. L No. 111-31, § 3(2),
123 Stat. 1776, 1781 (2009).
197. Lorillard Tobacco Co. v. Reilly, 533 U.S. 525, 547-48 (2001).
198. 21 U.S.C. § 387f(d)(1) (2012).
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The effect of tobacco marketing and promotion on America's
youth is probably the largest concern encompassed in the TCA,
and therefore, e-cigarette regulations should protect minors."'
Nearly half of the congressional findings in the TCA that address
the impact and effects of smoking and tobacco marketing on
younger populations evidence clear congressional concern.20 One
of the findings, in particular, summarizes this idea: "The use of
tobacco products by the Nation's children is a pediatric disease of
considerable proportions that results in new generations of tobac-
co-dependent children and adults."'01 To serve this primary pur-
pose of the TCA, the FDA should devise a regulatory scheme that
balances limiting minors' exposure to e-cigarettes with allowing
e-cigarettes to remain available to informed adults. By requiring
identification at purchase and restricting online e-cigarette sales
to websites that are able to accurately check a purchaser's age,
the FDA could drastically curb e-cigarette sales to minors, be-
cause currently, e-cigarettes are mainly sold over the Internet on
sites where minors are often not being screened for their age
when purchasing products.20 ' Though many states have enacted
legislation to prohibit sale of e-cigarettes to minors, this simply
illustrates the need for the FDA to move quickly in proposing
regulations that would fill the regulatory gaps the states have be-
gun to fill.20' After promulgation of a federal rule on e-cigarette
advertising and sales to minors, an expansive preemption clause
to the TCA should preempt state laws to avoid differing piece-
meal legislation enacted by various states.
The FDA should also prohibit advertising and other marketing
techniques that are clearly intended to target minors.204 The use
of candy-like flavorings such as grape, vanilla, and chocolate
tends to only appeal to young people and likely would not help
adults smoking combustible cigarettes switch to a potentially
199. See id. § 387 note (2012) (Findings).
200. See id.
201. Id. (Findings subsec. 1).
202. Customers can purchase e-cigarettes and any other necessary supplies from mall
kiosks and other specialty locations, but a large marketplace for e-cigarettes is the Inter-
net. See Fisher, supra note 80; Ilya Pozin, Electronic Cigarettes: Booming Industry or
Health Fiasco?, FORBES (Apr. 4, 2013), http://www.forbes.com/sites/ilyapozin/2013/04/11/
electronic-cigarettes-booming-industry-or-health-fiasco/.
203. See, e.g., CAL. HEALTH & SAFETY CODE § 119405(a) (West 2012) (making it unlaw-
ful to sell an e-cigarette "to a person under 18 years of age").
204. E-cigarettes have received significant criticism for allegedly targeting youth, espe-
cially because of their flavored nicotine cartridges. See, e.g., Bridget M. Kuehn, FDA Elec-
tronic Cigarettes May Be Risky, 302 J. AM. MED. ASS'N 937, 937 (2009).
1354 [Vol. 48:1319
FDA E-CIGARETTE REGULATION
less-harmful e-cigarette instead.20 ' Despite this implicit attempt
to market e-cigarettes to minors, evidence suggests that e-
cigarette manufacturers have not been too successful in attract-
ing minors that are new to tobacco products. Nine out of ten teen-
agers who tried e-cigarettes were already smokers, meaning that
e-cigarettes may actually serve as a successful harm reduction
technique keeping teens from using combustible cigarettes laced
with many more toxic and carcinogenic chemicals.206 Further, less
than ten percent of students surveyed from the sixth to twelfth
grades who have used e-cigarettes had never smoked a combus-
tible cigarette, and it very well could be that those students would
have used combustible cigarettes instead of starting with e-
cigarettes.2 07 Based on these survey results, e-cigarettes are large-
ly not attracting minors who have never smoked before, but the
government's interest in protecting minors from nicotine addic-
tion still justifies regulating e-cigarette advertisements.
Although evidence suggests that e-cigarettes may actually help
minors and adults who smoke find a potentially less-hazardous
alternative to cigarettes, regulating advertising and sales to mi-
nors similarly to combustible cigarettes upholds the overriding
purpose of the TCA. If an adult or a minor is not addicted to nico-
tine or smoking cigarettes, it cannot be in the best interest of pub-
lic health to attract new users to what could be a dangerous hob-
by-come-addiction.20 ' Removing flavoring additives and tempting
advertisements from the airwaves would help prevent attracting
new tobacco product users, but allowing some e-cigarette adver-
tisements where combustible cigarettes are traditionally sold,
such as convenience stores, would best serve the public interest
by having the option of a potentially less harmful nicotine deliv-
ery system available.
205. 21 U.S.C. § 387g(a)(7)(A) (2012) (noting that flavoring or coloring additives have
been banned from cigarettes in light of the fact that they might potentially be attractive to
minors); id. § 387(1) (defining additives to include "any substances intended for use as a
flavoring or coloring"); see Kuehn, supra note 204, at 937.
206. See Jacob Sullum, CDC Belatedly Reveals That Smoking By Teenagers Dropped
While Vaping Rose, FORBES (Nov. 20, 2013), http://www.forbes.com/sites/jacobsullum/2013
/1 1/20/cdc-belatedly-reveals-that-smoking-by-teenagers-dropped-while-vaping-rose/.
207. Notes From the Field: Electronic Cigarette Use Among Middle and High School
Students-United States, 2011-2012, CTRS. FOR DISEASE CONTROL & PREVENTION (Sept. 6,
2013), http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6235a6.htm.
208. Congress found that "[v]irtually all new users of tobacco products are under the
minimum legal age to purchase such products." 21 U.S.C. § 387 note (Findings subsec. 4).
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2. Labeling and Product Standards
The TCA grants the FDA authority to establish labeling and
product standards for tobacco products, and the FDA should uti-
lize this authority to ensure e-cigarette users are accurately in-
formed about the product they are using.20 ' The FDA should
promulgate a simple label requirement that e-cigarette packaging
contain some form of a nicotine comparison chart and a state-
ment that the product is not FDA approved. The "not FDA ap-
proved" label, which would include a short list of the potentially
harmful chemicals in e-cigarettes, would serve as a sufficient
warning to consumers that the product is not, in a sense, backed
by the FDA. Moreover, a short list of only the potentially harmful
chemicals in e-cigarettes would be sufficient to communicate any
necessary information to consumers curious about the safety of
the product. Combustible cigarette labels are only required to re-
port amounts of twenty different harmful chemicals on their
packaging, making it illogical to require e-cigarette manufactur-
ers to disclose more.1 o This requirement may actually work in fa-
vor of e-cigarettes, though, as instead of smokers being inundated
with the long list of harmful chemicals on the side of a cigarette
pack, e-cigarette users would probably only be confronted with a
short list of essentially all the ingredients: propylene glycol, wa-
ter, nicotine, and glycerin.'
In addition to labeling requirements, the FDA should regulate
e-cigarettes to ensure product standards are met and that the la-
beling on e-cigarette products contains accurate information. De-
spite the fact that e-cigarette devices themselves rarely malfunc-
tion, consistency in product standards should be universal
because e-cigarettes have been shown, though very infrequently,
to contain the wrong dosages of nicotine when compared with the
amount advertised.212 This could lead to consumer misinformation
209. Id. § 387g(a)(4)(C).
210. See Anna Yukhananov, FDA Big Tobacco Must Tell You What You're Smoking,
REUTERS (Mar. 30, 2012), http://www.reuters.com/article/2012/03/30/fda-tobacco-idUSL
2E8EU7DV20120330.
211. See Caponnetto et al., supra note 2, at 13.
212. See, e.g., Summary of Results: Laboratory Analysis of Electronic Cigarettes Con-
ducted by FDA, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/newsevents/publichealth
focus/ucml73146.htm (last updated July 22, 2009) [hereinafter Summary of Results]
("Three different electronic cigarette cartridges with the same label were tested and each
cartridge emitted a markedly different amount of nicotine with each puff. The nicotine
levels per puff ranged from 26.8 to 43.2 mcg nicotine/100 mL puff.").
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as well as consumers ingesting higher levels of nicotine than they
intended.' If e-cigarettes are being used to control nicotine in-
take without the additional chemicals that combustible cigarettes
contain, then it is critical that this information is clearly and ac-
curately communicated to consumers.
A simple regulation that would allow a universal product
standard that could be easily and efficiently checked by the FDA
is a simple light system on the e-cigarette itself.2 14 If all e-
cigarette manufacturers attached a sensor system on their e-
cigarettes that measured the amount of nicotine passing through
the atomizer and logged these amounts on a light scale, they
could quickly and accurately convey the necessary information to
the consumer.21 5 While this would likely increase the cost of e-
cigarettes, it is less costly than having the product taken off the
market and unavailable for sale. A light system, with each incre-
ment notating a fixed amount of nicotine inhaled, could also be
easily checked by the FDA for accuracy: simply check if the
amount of nicotine released and the light reading match. If a de-
vice is not working properly or transmitting the wrong infor-
mation, the FDA could label the product as "misbranded" until
the specific manufacturer fixed the issue.216 Regulation of the de-
vices themselves does not appear to be necessary as incident re-
ports are incredibly rare and can be properly handled through
another legal avenue such as products liability. 17
While e-cigarette labeling has, at times, been inconsistent in
properly communicating to users the amount of nicotine con-
sumed in using an e-cigarette, studies have shown that e-
cigarettes still generally appear to deliver less nicotine than com-
bustible tobacco cigarettes.2 18 Despite delivering fewer carcino-
213. See id.
214. See Paradise, supra note 173, at 371.
215. The apparent assumption is that the sensors would work and be accurate.
216. 21 U.S.C. § 387c (2012) (articulating criteria for being labeled as "misbranded").
217. There have been relatively few reported injuries in the United States from e-
cigarette use. For a product that has been on the market for several years, having relative-
ly few reported accidents is incredibly impressive. See Mikaela Conley, Man Suffers Severe
Injuries After E-Cigarette Explodes in His Mouth, ABC NEWS (Feb. 15, 2012), http://abc
news.go.com/Healthlelectric-cigarette-explodes-fla-mans-face/story?id=15645605; Electron-
ic Cigarette Explodes in Muskogee Woman's Hand, Fox23.COM (Apr. 18, 2012), http://
www.fox23.com/mostpopular/story/Electronic-cigarette-explodes-in-Muskogee-womans/ek
2x6P6rvkyLu5cMrvGwVQ.cspx.
218. Richard J. O'Connor, Non-cigarette Tobacco Products: What Have We Learnt and
Where Are We Headed?, 21 TOBACCO CONTROL 181, 183-84 (2012). Further, although the
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gens and less nicotine than combustible cigarettes, e-cigarettes
should still be regulated to assure that the products are clearly
and accurately conveying information to their user. A simple note
("not FDA approved"), short ingredient list, and nicotine light
system could be utilized to convey adequate, accurate information
to consumers using e-cigarettes while also keeping the products
available to the public.
B. Additional TCA Provisions the FDA Should Focus on Less
Aside from advertising, sale to minors, product labeling, and
product standards, the FDA should abstain from asserting any
other regulatory authority under the TCA. Instead, basic guide-
lines for e-cigarette manufacturers to reference when developing
their products would be enormously helpful in developing a safe
and effective product for those looking for an alternative to com-
bustible cigarettes while keeping e-cigarettes on the market and
available to those who could benefit from them.
1. Disclosure of Ingredients and Pre-Market Approval
The TCA gives the FDA sweeping regulatory power when it
comes to ingredient disclosure and reporting, but because of the
scrutiny e-cigarettes have already received prior to any successful
FDA regulatory attempts, the FDA already has most of this data.
Specifically, though, the TCA authorizes the FDA to require test-
ing and reporting of ingredients by each e-cigarette manufactur-
er.21 While all ingredients must be disclosed, it appears most im-
portant that the "harmful and potentially harmful constituents"
("HPHC") be reported in accordance with the FDA's updated
HPHC list.220 This will make a required disclosure quite simple.
While this list appears daunting and akin to a regulatory inferno,
the benefit with e-cigarettes is that "we actually have a much bet-
FDA can regulate nicotine yield standards under the TCA as well, because e-cigarettes
generally deliver less nicotine than combustible cigarettes, setting a requirement con-
sistent with that for tobacco cigarettes would likely not have an effect on the e-cigarette
industry. See 21 U.S.C. § 387g(a)(4)(A)(i) (2012).
219. 21 U.S.C. § 387d (2012).
220. Id. § 387d(e); Harmful and Potentially Harmful Constituents in Tobacco Products
and Tobacco Smoke: Established List, U.S. FOOD & DRUG ADMIN., http://www.fda.gov
/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm (last visit-
ed Apr. 14, 2014).
1358 [Vol. 48:1319
FDA E-CIGARETTE REGULATION
ter idea what is in electronic cigarette vapor than what is in to-
bacco smoke."221 E-cigarettes have fewer toxic effects than tradi-
tional cigarettes and evidence also suggests that they are safer
than traditional cigarettes-arguments that e-cigarettes are not
safe nearly all stem from the argument that there is not enough
information to declare them safe rather than definitive evidence
to say that e-cigarettes are actually not safe.m2 ' Granted, e-
cigarettes surely bring a general uncertainty due to their novelty,
but all of the actual ingredients found in e-cigarettes have been
studied, and approved, in one form or another by the FDA. In
fact, the ingredients that predominantly compose e-cigarettes are
water, nicotine, propylene glycol, and glycerin: all of which are
safe or have been formerly approved by the FDA.22 3 Consequently,
because the FDA has already approved all the e-cigarette ingre-
dients, requiring further testing is simply inefficient.
The FDA keeps a running list of potential e-cigarette risks on
its website to keep consumers informed about the products. 2 4 As
a result of several scientific studies, the agency found carcinogen-
ic materials in e-cigarettes that may be transmitted to users.225
However, the chemical contaminants found by the FDA, particu-
larly nitrosamines, exist in e-cigarettes at an immensely lower
rate than in approved combustible cigarettes. 226 Even within the
same nicotine alternatives industry, nicotine patches that often
contain the same amount of nitrosamines have been approved by
221. Jacob Sullum, The Lunatic War on E-Cigarettes, N.Y. POST (Oct. 23, 2013), http:
//www.nypost.com/2013/10/23/the-lunatic-war-on-e-cigarettes/ (internal quotation marks
omitted) (statement of public-health professor Michael Siegel).
222. See O'Connor, supra note 218, at 184.
223. See Caponnetto et al., supra note 2, at 13. Water is obviously not harmful and for
a more detailed analysis of nicotine, see supra Part III.A. Propylene glycol is approved by
the FDA for many different pharmaceuticals, has undergone extensive testing, and is used
in many different food and other consumer products. See id.
224. Electronic Cigarettes, supra note 48. According to the FDA's website, there may be
risks in the normal operations of e-cigarettes given that there have been reports of various
e-cigarette related illnesses and hospitalizations. Id.; see also FDA Warns of Health Risks
Posed by E-Cigarettes, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/ForConsumers/con
sumerupdates/ucml73401.htm (last visited Apr. 14, 2014) (reiterating the FDA's concern
about e-cigarettes' risks including increased addiction among young people, potential for
youth to experiment with other tobacco products, and the uncertainty of potentially toxic
ingredients).
225. See Electronic Cigarettes, supra note 48; see also Summary of Results, supra note
212.
226. See Cahn & Siegel, supra note 179, at 18 (finding that combustible cigarettes con-
tain 500 to 1400 times the amount of nitrosamines than what the FDA found in e-
cigarettes).
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the FDA as safe and effective.22 7 Only trace amounts of nitrosa-
mines in the "high nicotine" cartridge of one brand of e-cigarettes
was found at a similar amount already present in a nicotine
patch.2 28 E-cigarettes, based on their ingredients, must be consid-
ered safe, or at least much safer than their combustible cigarette
counterparts. Therefore, the isolated incidence of nitrosamines in
e-cigarettes should not require the FDA to further regulate e-
cigarettes beyond the extent suggested above because conven-
tional cigarettes and other nicotine delivery devices have similar,
or greater, nitrosamine levels.
The FDA has also discovered other harmful chemicals, glycerin
and diethylene glycol ("DEG"), in some e-cigarette fluid, but yet
again the substances were only found in a small sample of e-
cigarettes at a very low rate.229 In fact, after finding DEG in one
cartridge tested in 2009, at least fifteen studies were conducted
by different researchers and all failed to find any evidence of this
chemical in any other e-cigarettes.2 30 When the FDA actually
found DEG in one of the eighteen e-cigarettes samples, the sub-
stance only composed one percent of the nicotine fluid, which is
not a toxic quantity for humans."' While seeing DEG on an in-
gredient list may be troubling for some, recognizing its very min-
imal, non-toxic presence in e-cigarettes should calm concern.
E-cigarette manufacturers should submit their full ingredient
listings to the FDA, but due to the testing that has already been
done on the products, the lack of significant findings, and the po-
tential that e-cigarettes have to counteract the harmful effects of
smoking combustible cigarettes, the FDA should not require any
form of pre-market approval for e-cigarettes already being sold.
Pre-market approval of new e-cigarettes entering the market
should simply entail demonstrating that the product is nearly
identical to those already on the market. The logic behind allow-
ing e-cigarettes to stay on the market is simple: e-cigarettes "de-
227. Daniel F. Hardin, Blowing Electronic Smoke: Electronic Cigarettes, Regulation,
and Protecting the Public Health, 2011 U. ILL. J.L. TECH. & POLY 433, 446 (2011); see Ca-
ponnetto et al., supra note 2, at 14 tbl.1.
228. See Caponnetto et al., supra note 2, at 13, 14 tbl.1.
229. See Summary of Results, supra note 212.
230. Cahn & Siegel, supra note 179, at 18; Roxanne Palmer, E-Cigarettes as Effective
as Nicotine Patches in Helping Smokers Quit: Study, INT'L BUS. TIMES (Sept. 8, 2013),
http://www.ibtimes.comle-cigarettes-effective-nicotine-patches-helping-smokers-quit-study
-1403523.
231. See Caponnetto et al., supra note 2, at 13-14.
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liver a nicotine vapor without the combustion products . . . re-
sponsible for nearly all of [combustible cigarette] smoking's harm-
ful effects."' When given only the options of smoking cigarettes
or completely giving up nicotine, many smokers will refuse to give
up cigarettes and, instead, will continue their addiction; this is
the scenario the FDA could force e-cigarette users into.3 The
FDA should not be forcing the people it is responsible for protect-
ing into a harmful scenario. The ingredients in e-cigarettes may
certainly contribute to nicotine dependence, "but the desire of a
cigarette-free world is just that-a dream. ... [especially because
of] nicotine's beneficial effects such as the improved ability to pay
attention, concentrate and remember, as well as the capacity of
relieving symptoms of mood impairments."23 4 A pragmatic re-
sponse by the FDA, in the best interest of the public health, is to
not require onerous regulatory procedures restricting and poten-
tially eliminating access to these lower-risk products.
2. Products with Therapeutic Claims
As discussed, the FDA has jurisdictional authority to regulate
e-cigarettes claiming therapeutic effects that are different than
customarily marketed cigarettes, and at this point, courts have
held that e-cigarettes do not make therapeutic claims.235 Congress
was clear that the FDA should have authority over products ex-
pressly claiming a therapeutic benefit, but the FDA has not been
clear about its interpretation of what constitutes a therapeutic
product. The FDA should focus on making their interpretation of
the FDCA more clear. Two and one-half years ago, the FDA con-
sidered issuing a guidance document regarding therapeutic
claims and triggers for regulation as a drug or medical device, but
it has failed to follow through.2 36 E-cigarette manufacturers only
have prior case law to attempt to adhere to, but because of the
novelty of the e-cigarette industry and the incessant attempts of
the FDA to regulate e-cigarettes improperly under the FDCA, it is
anything but clear what the FDA may consider a therapeutic
claiming product.
232. Id. at 14.
233. See id. at 16.
234. Id.
235. See supra Part III.B.
236. See Deyton & Woodcock, supra note 15.
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A large amount of e-cigarette advertising appears just like a
recent FIN, an e-cigarette manufacturer, promotional: a bar scene
where a few e-cigarette users are able to vape their e-cigarettes in
public having vapor trailing behind them while doing it.' While
this type of commercial does not appear to advertise e-cigarettes
as "therapeutic," more guidance is necessary from the FDA to
prevent e-cigarette manufacturers from unanticipated FDCA
regulation should their promotion of the product make "therapeu-
tic" claims.
C. State and Local Options and Smoking Bans
If e-cigarettes are eventually regulated under the TCA, the
statute explicitly preserves the right of the state and local gov-
ernments to restrict the sale, distribution, and possession of to-
bacco products as they see necessary.238 This can be done by to-
bacco tax laws, which arguably have the strongest effect on the
price of tobacco products, but another option is through amending
smoke-free laws that ban smoking to include a vaping ban.239
Smoke-free laws often define "smoking" as "the burning of ...
[any] matter or substance which contains tobacco or any other
matter that can be smoked."2 40 But e-cigarettes are not burned-
instead they are vaped. Unless amended, these smoke-free laws
likely will not cover e-cigarettes, but because these laws are pri-
marily designed to protect non-consenting individuals in public
from being exposed to dangerous secondhand smoke, e-cigarettes
do not pose as large of a problem.2 4' Regardless, states and locali-
237. FIN Electronic Cigarettes: Rewrite the Rules, YOUTUBE (May 25, 2013), http://
www.youtube.com/watch?v-zvUFgVxs_7k.
238. 21 U.S.C. § 387p(a)(1) (2012). See generally Michael Freiberg, Options for State
and Local Governments to Regulate Non-Cigarette Tobacco Products, 21 ANNALS HEALTH
L. 407 (2012) (discussing state and local regulatory options after enactment of the TCA).
239. Freiberg, supra note 238, at 416.
240. See, e.g., N.J. STAT. ANN. § 26:3D-57 (West 2006) (emphasis added).
241. See Letter from Kenneth T. Cuccinelli, II, Att'y Gen., Commonwealth of Va., to
Christopher K. Peace, Member, House of Delegates, Commonwealth of Va. (Apr. 27, 2010),
available at http://www.oag.state.va.us/opinions%20and%201egal%20resources/opinions/
2010opns/10-029-peace.pdf (stating that traditional cigarettes burn "carbonaceous materi-
als" with small particle byproducts, whereas vapor is similar to water evaporating from a
tea kettle); see also Patrick Kabat, Note, "Till Naught but Ash Is Left to See"- Statewide
Smoking Bans, Ballot Initiative, and the Public Sphere, 9 YALE J. HEALTH POL'Y L. &
ETHICS 128, 136 (2009) (identifying secondhand smoke as a "serious public health hazard"
per several Surgeons General). As recently as December 30, 2013, some localities have
adopted legislation to regulate e-cigarette usage in the same way combustible cigarettes
are regulated. See, e.g., Morgan Winsor, Bloomberg Signs His Last 22 Bills; One Regulates
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ties believing their constituents would benefit from smoking bans
amended to include e-cigarettes would likely be permitted to pass
such laws by referring to the potential health risks associated
with e-cigarettes and a locality's "current public health laws gov-
erning indoor smoking bans" because the federal government has
"been slow to respond meaningfully" to e-cigarette regulation."242
Notwithstanding, amending public smoking bans is an option
available to states and localities that do not feel that a minimalist
approach to e-cigarette regulation is sufficient.
States and localities are often uniquely situated to enforce a
more personalized, effective regulatory regime simply based on
their more localized concerns and deeper understanding of their
respective constituents. Regarding e-cigarettes specifically, there
is virtually no current federal regulation, and therefore, states
and localities have been left with the opportunity to take regula-
tory initiative; they have done just that.243 The FDA need not re-
main absent from e-cigarette regulation, as discussed already, but
an observation of the past few years suggests that states and lo-
calities are well-equipped to address regulatory gaps and increase
protection where necessary. For example, in Kuhn v. County of
Suffolk the Suffolk County, New York legislature found e-
cigarettes to be harmful, issued a local law "banning the sale of e-
cigarettes to individuals under nineteen," and banning the use of
e-cigarettes in all public forums.2 " Despite the petitioners conten-
tion that the law, Resolution No. 717-2009, was arbitrary and ca-
pricious, a court determined that the resolution was a valid exer-
cise of governmental power because it had a rational basis,
supported by facts and information, to anticipate a potential dan-
ger and "provide against it before it materializes."2 4 Presently,
thirty-nine states, the District of Columbia, and 3964 municipali-
ties have laws in place restricting smoking in public, similar to
E-Cigarette Use, CNN (Dec. 30, 2013), http://www.cnn.com/2013/12/30/politics/mayor-
bloomberg-last-bills/.
242. Suffolk Cnty., N.Y., Res. No. 717, § 1 (Apr. 28, 2009). Again, this rationale is not
necessarily consistent with the primary rationale behind most state-wide/local public
smoking bans-to prevent smokers from imposing negative externalities on others by cre-
ating hazardous tobacco smoke-because there is no evidence that electronic cigarettes
could create health hazards to anyone not directly using the product. See Thomas A. Lam-
bert, The Case Against Smoking Bans, 13 Mo. ENVTL. L. & POL'Y REV. 94, 95-96 (2005).
243. See, e.g., Kuhn v. Cnty. of Suffolk, No. 48869/2009, 2010 N.Y. Misc. LEXIS 5224
*2-3 (N.Y. Sup. Ct. Oct. 15, 2010).
244. Id. at *2-3.
245. Id. at *8-9.
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the restriction in Kuhn, supporting the idea that states and mu-
nicipalities certainly have the ability to react to their respective
local conditions in a manner that is best for their constituents.2
There are several examples similar to Suffolk County, but,
even where absent, a lack of local or state regulation does not
mean that state or local government is unable to pass similar leg-
islation. Instead, it may actually suggest that the respective lo-
cale does not believe a regulation is needed or that the state may
believe e-cigarettes are a safer alternative to combustible ciga-
rettes. Whereas areas like Suffolk County, a population-dense
county making up over half of Long Island, may experience issues
with e-cigarettes causing "fear, stress and confusion" in public
places where combustible cigarettes are banned, other areas may
not have the same issue.2 47 Less populous states like Nevada and
Kentucky, for example, may actually want to encourage their
combustible cigarette-saturated counties to make the switch to e-
cigarettes for a variety of reasons; one may be that the state may
believe e-cigarettes are a safer alternative to combustible ciga-
rettes.24 8
States and localities may also simply follow a "social norm" ra-
tionale, theorizing that permitting e-cigarette use in the public
domain makes traditional cigarette smoking seem acceptable. 2 49
While this rationale seems to underestimate human intelligence
and situational awareness, it is nevertheless still an option for
greater regulation if particular states and localities feel that it is
necessary.2 50 Arguments may also be made for consistency and en-
forcement of a smoking ban, because otherwise regulating smok-
ing in the public domain could quickly become an "enforcement
246. Overview List-How Many Smokefree Laws?, AM. NONSMOKERS RIGHTS FOUND.
http://www.no-smoke.org/pdf/mediaordlist.pdf (last updated Jan. 2, 2014).
247. Suffolk Cnty., N.Y., Res. No. 717, § 1 (Apr. 28, 2009); Kuhn, 2010 N.Y. Misc.
LEXIS 5524, at *3.
248. See Demographics of Tobacco Use, ORAL CANCER FOUND., http://www.oralcancer
foundation.org/tobacco/demographics.php (last visited Apr. 14, 2014) (finding that smoking
prevalence among adults in Nevada is 31.5% and in Kentucky is 29.7%).
249. Vanessa Ho, King County Bans Public E-Cigarette Smoking, SEATILE POST-
INTELLIGENCER (Dec. 15, 2010), http://www.seattlepi.com/locallarticle/King-County-bans-
public-e-cigarette-smoking-904130.php.
250. See id. (claiming traditional smokers who see a vaper using in public receives a
"powerful subliminal message" that smoking in public is acceptable).
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nightmare."2 Of course, these bans may be challenged, but the
chances of success for petitioners are quite low.25 2
States may also have the ability to act more quickly than the
federal government and can deal directly with the e-cigarette
manufacturers. For example, in October of 2010, California
brought a suit against Smoking Everywhere to stop the company
from targeting sales and advertising to minors and claiming that
its products are safe alternatives to tobacco.' Smoking Every-
where settled the case and agreed to California's demands.2 54 Alt-
hough this approach is typically not favored by the e-cigarette in-
dustry, it is nonetheless another regulatory option. 255 E-cigarette
manufacturers have a strong interest in less regulation, and if
meeting the demands of particular states means keeping their
product on the market and avoiding a stricter regulatory option,
e-cigarette manufacturers will respect the particular state's bar-
gaining power. That is exactly what happened in the case of
Smoking Everywhere in California.
A distinct feature of the TCA is the ample authority expressly
preserved to state and local governments to regulate tobacco
products.25 6 Congress was careful to not limit the authority of
states to "enact . .. any law, rule, [or] regulation . .. with respect
to tobacco products" that strengthens requirements already set
forth in the TCA.257 With a minimalist federal structure balancing
basic protection from the potential risks e-cigarettes present
while keeping the vaporizers available for consumers and past
smokers, states would be well situated to identify potential issues
251. Suffolk Cnty., N.Y., Res. No. 717, § 1 (Apr. 28, 2009).
252. See Jordan Raphael, Note, The Calabasas Smoking Ban: A Local Ordinance Points
the Way for the Future of Environmental Tobacco Smoke Regulation, 80 S. CAL. L. REV.
393, 401, 403-06 (2007) (discussing the case law on local smoking bans); Inclusion of E-
Cigarette in Smoking Ban Has Some Users Feeling Burned, WAVE 3 NEWS (Apr. 7, 2011),
http://www.wave3.com/story/14406057/inclusion-of-e-cigarette-in-smoking-ban-has-some-
users-feeling-burned.




255. Eliza Gray, Regulating E-Cigarettes Could Have Unintended Consequences, TIME
(Dec. 16, 2013), http://www.nation.time.com/2013/12/16/regulating-e-cigarettes-could-have-
unintended-consequences/. Miguel Martin, the president of an electronic cigarette manu-
facturer in New Jersey says he is "looking forward to federal regulation. But each state
doing its own thing in absence of a federal framework ... is a mistake." Id.
256. See 21 U.S.C. § 387p(a)(1) (2012).
257. Id.
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for their particular constituencies and address them through
amending or enacting legislation.
V. CONCLUSION
The FDA surely has an interest to ensure the safety of e-
cigarettes, but to the extent e-cigarettes pose any specific and
imminent risk of harm, the TCA authorizes the FDA to compre-
hensively regulate e-cigarette's manufacture, sale, advertising,
and labeling. E-cigarette manufacturers have acknowledged the
FDA's ability to do just that. The FDA, on the other hand has
stubbornly continued attempting to regulate e-cigarettes under
the FDCA, which is simply not structured to regulate non-
cigarette tobacco products without producing the absurd result of
banning tobacco products all together. The FDA has recently an-
nounced its intention to regulate e-cigarettes under the TCA, as it
should have from the beginning, but no regulation has been pro-
posed yet."' Assuming that the FDA will carry through with its
promise, it should take a minimalist approach to e-cigarette regu-
lation under the TCA.
People are going to remain addicted to nicotine, and e-
cigarettes appear to provide nicotine in a much safer way than
traditional, combustible cigarettes. Left with a choice between the
two, e-cigarettes are the better choice; however, the FDA's prior
attempts to regulate the vaporizers under the stringent provi-
sions of the FDCA imply that proposed regulations under the
TCA, the proper regulatory avenue, will be stringent as well.
Adopting a strict regulatory scheme that will require pre-market
approval for a product that is already being used effectively could
waste time. More importantly, it could force e-cigarette users to
focus their nicotine addiction back on traditional, combustible
cigarettes, the same combustible cigarettes laced with over sixty
carcinogenic chemicals not found in e-cigarettes. By regulating
advertising, labeling, and general product standards, the FDA
can reasonably ensure the safety of e-cigarettes, which in turn
will reduce the number of combustible cigarette smokers. A min-
imalist regulatory structure is a win-win scenario for the FDA:
requiring a baseline level of safety and consistency while fulfilling
258. See Electronic Cigarettes, supra note 48; Alec Torres, Government War on E-





the agency's primary purpose to promote public health, which, in
this case, is achieved through a reduced-risk product. E-cigarettes
should be seen as a solution to endemic issues yet to be solved:
cigarette smoking and tobacco-related death. Instead of taking a
stringent, overly cautious regulatory approach, the FDA should
ensure a minimum safety threshold while keeping e-cigarettes
available to those that need them.
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